CN116870157A - 皮肤障碍改善用组合物 - Google Patents
皮肤障碍改善用组合物 Download PDFInfo
- Publication number
- CN116870157A CN116870157A CN202310702778.6A CN202310702778A CN116870157A CN 116870157 A CN116870157 A CN 116870157A CN 202310702778 A CN202310702778 A CN 202310702778A CN 116870157 A CN116870157 A CN 116870157A
- Authority
- CN
- China
- Prior art keywords
- extract
- acid
- skin
- expression
- atmospheric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- 208000017520 skin disease Diseases 0.000 title claims abstract description 80
- 230000014509 gene expression Effects 0.000 claims abstract description 176
- 239000000126 substance Substances 0.000 claims abstract description 94
- 239000003344 environmental pollutant Substances 0.000 claims abstract description 90
- 231100000719 pollutant Toxicity 0.000 claims abstract description 90
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 68
- 239000003112 inhibitor Substances 0.000 claims abstract description 67
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 53
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract description 53
- 230000036542 oxidative stress Effects 0.000 claims abstract description 42
- 102000017761 Interleukin-33 Human genes 0.000 claims abstract description 41
- 108010067003 Interleukin-33 Proteins 0.000 claims abstract description 41
- 230000001737 promoting effect Effects 0.000 claims abstract description 38
- 239000000284 extract Substances 0.000 claims description 303
- 235000002639 sodium chloride Nutrition 0.000 claims description 135
- 150000003839 salts Chemical class 0.000 claims description 124
- -1 hyaluronic acid oligosaccharide Chemical class 0.000 claims description 79
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 54
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 54
- 229920002674 hyaluronan Polymers 0.000 claims description 46
- 229960003160 hyaluronic acid Drugs 0.000 claims description 46
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 44
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 42
- 239000000428 dust Substances 0.000 claims description 29
- 235000012000 cholesterol Nutrition 0.000 claims description 27
- 235000013399 edible fruits Nutrition 0.000 claims description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 23
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 22
- 229960000458 allantoin Drugs 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 22
- 235000019106 Cynara scolymus Nutrition 0.000 claims description 21
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 21
- 229960003720 enoxolone Drugs 0.000 claims description 21
- 244000019459 Cynara cardunculus Species 0.000 claims description 20
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 20
- 239000000356 contaminant Substances 0.000 claims description 20
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 19
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 19
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 19
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 19
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 19
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 19
- 229960000401 tranexamic acid Drugs 0.000 claims description 19
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 claims description 16
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 16
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 16
- 201000004624 Dermatitis Diseases 0.000 claims description 15
- 229920002527 Glycogen Polymers 0.000 claims description 15
- 235000016357 Mirtillo rosso Nutrition 0.000 claims description 15
- 241000220317 Rosa Species 0.000 claims description 15
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 claims description 15
- 244000077923 Vaccinium vitis idaea Species 0.000 claims description 15
- 229960000520 diphenhydramine Drugs 0.000 claims description 15
- 229940096919 glycogen Drugs 0.000 claims description 15
- 208000003251 Pruritus Diseases 0.000 claims description 14
- 230000008591 skin barrier function Effects 0.000 claims description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 13
- 235000004347 Perilla Nutrition 0.000 claims description 13
- 244000124853 Perilla frutescens Species 0.000 claims description 13
- 239000004576 sand Substances 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 12
- 229960004194 lidocaine Drugs 0.000 claims description 12
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 claims description 11
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims description 11
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 claims description 11
- 230000007803 itching Effects 0.000 claims description 11
- 241000195493 Cryptophyta Species 0.000 claims description 10
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- 235000020221 chamomile extract Nutrition 0.000 claims description 10
- 229940119217 chamomile extract Drugs 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 235000011147 magnesium chloride Nutrition 0.000 claims description 10
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 10
- 235000002020 sage Nutrition 0.000 claims description 10
- 230000037303 wrinkles Effects 0.000 claims description 10
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 9
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims description 9
- 240000000982 Malva neglecta Species 0.000 claims description 9
- 235000000060 Malva neglecta Nutrition 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 159000000000 sodium salts Chemical class 0.000 claims description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 229940082880 azadirachta indica flower extract Drugs 0.000 claims description 7
- 244000062730 Melissa officinalis Species 0.000 claims description 6
- 229940094952 green tea extract Drugs 0.000 claims description 6
- 235000020688 green tea extract Nutrition 0.000 claims description 6
- AVBJHQDHVYGQLS-UHFFFAOYSA-N 2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)NC(C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-UHFFFAOYSA-N 0.000 claims description 5
- 244000144730 Amygdalus persica Species 0.000 claims description 5
- 241001105098 Angelica keiskei Species 0.000 claims description 5
- 235000003826 Artemisia Nutrition 0.000 claims description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 5
- 244000077995 Coix lacryma jobi Species 0.000 claims description 5
- 235000019766 L-Lysine Nutrition 0.000 claims description 5
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 5
- 229940089116 arnica extract Drugs 0.000 claims description 5
- 244000030166 artemisia Species 0.000 claims description 5
- 235000009052 artemisia Nutrition 0.000 claims description 5
- 229940007062 eucalyptus extract Drugs 0.000 claims description 5
- 229940083980 lavender extract Drugs 0.000 claims description 5
- 235000020723 lavender extract Nutrition 0.000 claims description 5
- 229940084038 salix alba bark extract Drugs 0.000 claims description 5
- 235000020240 turmeric extract Nutrition 0.000 claims description 5
- 239000008513 turmeric extract Substances 0.000 claims description 5
- 229940052016 turmeric extract Drugs 0.000 claims description 5
- 208000010201 Exanthema Diseases 0.000 claims description 4
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 4
- 230000003628 erosive effect Effects 0.000 claims description 4
- 201000005884 exanthem Diseases 0.000 claims description 4
- 206010037844 rash Diseases 0.000 claims description 4
- 241000109365 Rosa arkansana Species 0.000 claims description 3
- 235000005066 Rosa arkansana Nutrition 0.000 claims description 3
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 3
- 241001672694 Citrus reticulata Species 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 claims description 2
- 235000002912 Salvia officinalis Nutrition 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims 2
- 235000011201 Ginkgo Nutrition 0.000 claims 1
- 244000194101 Ginkgo biloba Species 0.000 claims 1
- 235000008100 Ginkgo biloba Nutrition 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 230000004888 barrier function Effects 0.000 abstract description 24
- 230000028993 immune response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 113
- 210000003491 skin Anatomy 0.000 description 74
- 239000002609 medium Substances 0.000 description 72
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 54
- 238000000034 method Methods 0.000 description 48
- 238000012360 testing method Methods 0.000 description 39
- 230000000694 effects Effects 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 32
- 238000012258 culturing Methods 0.000 description 31
- 239000001569 carbon dioxide Substances 0.000 description 27
- 229910002092 carbon dioxide Inorganic materials 0.000 description 27
- 229940107161 cholesterol Drugs 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 238000011529 RT qPCR Methods 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 22
- 239000000809 air pollutant Substances 0.000 description 21
- 231100001243 air pollutant Toxicity 0.000 description 21
- 238000005259 measurement Methods 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 20
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 16
- 229920001296 polysiloxane Polymers 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000011575 calcium Substances 0.000 description 15
- 239000002537 cosmetic Substances 0.000 description 15
- 210000002615 epidermis Anatomy 0.000 description 15
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 14
- 241000207199 Citrus Species 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 14
- 239000013256 coordination polymer Substances 0.000 description 14
- 239000006071 cream Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 235000020971 citrus fruits Nutrition 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- 238000001061 Dunnett's test Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 235000016520 artichoke thistle Nutrition 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 11
- 238000000692 Student's t-test Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 229940109850 royal jelly Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000003204 osmotic effect Effects 0.000 description 10
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000002752 melanocyte Anatomy 0.000 description 9
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 235000019486 Sunflower oil Nutrition 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 229940069445 licorice extract Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000419 plant extract Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000002600 sunflower oil Substances 0.000 description 8
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 7
- 102100040836 Claudin-1 Human genes 0.000 description 7
- 238000008157 ELISA kit Methods 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 description 7
- 102100030416 Stromelysin-1 Human genes 0.000 description 7
- 244000269722 Thea sinensis Species 0.000 description 7
- 102000003425 Tyrosinase Human genes 0.000 description 7
- 108060008724 Tyrosinase Proteins 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229940083542 sodium Drugs 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229940010747 sodium hyaluronate Drugs 0.000 description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 108050009302 Claudin Proteins 0.000 description 6
- 102000002029 Claudin Human genes 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108091092584 GDNA Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- 229940059958 centella asiatica extract Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000167854 Bourreria succulenta Species 0.000 description 5
- 240000001548 Camellia japonica Species 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 244000000626 Daucus carota Species 0.000 description 5
- 235000002767 Daucus carota Nutrition 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 5
- 239000009141 Houttuynia cordata plant extract Substances 0.000 description 5
- 244000246386 Mentha pulegium Species 0.000 description 5
- 235000016257 Mentha pulegium Nutrition 0.000 description 5
- 235000004357 Mentha x piperita Nutrition 0.000 description 5
- 238000011530 RNeasy Mini Kit Methods 0.000 description 5
- 235000011449 Rosa Nutrition 0.000 description 5
- 235000007303 Thymus vulgaris Nutrition 0.000 description 5
- 240000002657 Thymus vulgaris Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 229940106189 ceramide Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000019693 cherries Nutrition 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 235000018597 common camellia Nutrition 0.000 description 5
- 239000000287 crude extract Substances 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 5
- 235000021186 dishes Nutrition 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 235000001050 hortel pimenta Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000001585 thymus vulgaris Substances 0.000 description 5
- 210000001578 tight junction Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 4
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 235000005206 Hibiscus Nutrition 0.000 description 4
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 4
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 4
- 101001086785 Homo sapiens Occludin Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- 102100032604 Occludin Human genes 0.000 description 4
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 241000972673 Phellodendron amurense Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004721 Polyphenylene oxide Substances 0.000 description 4
- 240000002547 Rosa roxburghii Species 0.000 description 4
- 235000000640 Rosa roxburghii Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 4
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 229940097043 glucuronic acid Drugs 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002484 inorganic compounds Chemical class 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 229960000448 lactic acid Drugs 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 description 3
- 244000247747 Coptis groenlandica Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 3
- 244000061508 Eriobotrya japonica Species 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241001071917 Lithospermum Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 235000000539 Rosa canina Nutrition 0.000 description 3
- 240000008530 Rosa canina Species 0.000 description 3
- 235000010337 Rosa dumalis Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000000591 Tight Junction Proteins Human genes 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 3
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 229960004275 glycolic acid Drugs 0.000 description 3
- 102000053148 human MMP1 Human genes 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229960001679 octinoxate Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229940055726 pantothenic acid Drugs 0.000 description 3
- 239000011713 pantothenic acid Substances 0.000 description 3
- 235000019161 pantothenic acid Nutrition 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 235000020955 thiamine monophosphate Nutrition 0.000 description 3
- 239000011621 thiamine monophosphate Substances 0.000 description 3
- GUGWNSHJDUEHNJ-UHFFFAOYSA-N thiamine(1+) monophosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N GUGWNSHJDUEHNJ-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 238000001363 water suppression through gradient tailored excitation Methods 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 235000016413 Actinidia polygama Nutrition 0.000 description 2
- 240000006274 Actinidia polygama Species 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 240000005343 Azadirachta indica Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 241000555678 Citrus unshiu Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 239000009513 Coptidis rhizoma extract Substances 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- 241001289529 Fallopia multiflora Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 235000013500 Melia azadirachta Nutrition 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 101710151715 Protein 7 Proteins 0.000 description 2
- 235000000656 Rosa multiflora Nutrition 0.000 description 2
- 244000050053 Rosa multiflora Species 0.000 description 2
- 235000004828 Rosa odorata Nutrition 0.000 description 2
- 240000002289 Rosa odorata Species 0.000 description 2
- 241000207929 Scutellaria Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 206010052568 Urticaria chronic Diseases 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000003915 air pollution Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229950004580 benzyl nicotinate Drugs 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 229940099417 ceramide 2 Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 208000024376 chronic urticaria Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 102000056609 human MMP3 Human genes 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229940055350 kiwi fruit extract Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229960002337 magnesium chloride Drugs 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 150000002814 niacins Chemical class 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000000791 photochemical oxidant Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical class Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- IWLROWZYZPNOFC-UHFFFAOYSA-O thiamine triphosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N IWLROWZYZPNOFC-UHFFFAOYSA-O 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- OAJLVMGLJZXSGX-CXGXMSGESA-L (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4z,9z,14z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8 Chemical compound [Co+3].O[C@@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.O([C@H]1[C@H]([C@H](O[C@@H]1CO)N1C2=CC(C)=C(C)C=C2N=C1)O)P([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O OAJLVMGLJZXSGX-CXGXMSGESA-L 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- MFYAQFYIDXXKQG-MLCQCVOFSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(hexadecanoylamino)-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O MFYAQFYIDXXKQG-MLCQCVOFSA-N 0.000 description 1
- SDOFMBGMRVAJNF-VANKVMQKSA-N (2s,3s,4s,5r)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO SDOFMBGMRVAJNF-VANKVMQKSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- QWOZZTWBWQMEPD-UHFFFAOYSA-N 1-(2-ethoxypropoxy)propan-2-ol Chemical compound CCOC(C)COCC(C)O QWOZZTWBWQMEPD-UHFFFAOYSA-N 0.000 description 1
- VUICSPKQAQGLBU-UHFFFAOYSA-N 1-(4-methylphenyl)ethyl pyridine-3-carboxylate Chemical compound C=1C=C(C)C=CC=1C(C)OC(=O)C1=CC=CN=C1 VUICSPKQAQGLBU-UHFFFAOYSA-N 0.000 description 1
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical compound CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 1
- CLWAXFZCVYJLLM-UHFFFAOYSA-N 1-chlorohexadecane Chemical compound CCCCCCCCCCCCCCCCCl CLWAXFZCVYJLLM-UHFFFAOYSA-N 0.000 description 1
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- DRGAZIDRYFYHIJ-UHFFFAOYSA-N 2,2':6',2''-terpyridine Chemical compound N1=CC=CC=C1C1=CC=CC(C=2N=CC=CC=2)=N1 DRGAZIDRYFYHIJ-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- DJCYDDALXPHSHR-UHFFFAOYSA-N 2-(2-propoxyethoxy)ethanol Chemical compound CCCOCCOCCO DJCYDDALXPHSHR-UHFFFAOYSA-N 0.000 description 1
- XYVAYAJYLWYJJN-UHFFFAOYSA-N 2-(2-propoxypropoxy)propan-1-ol Chemical compound CCCOC(C)COC(C)CO XYVAYAJYLWYJJN-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- YBRJTUFWBLSLHY-UHFFFAOYSA-N 2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC YBRJTUFWBLSLHY-UHFFFAOYSA-N 0.000 description 1
- UHDPBLMLEMNPKP-UHFFFAOYSA-M 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol thiocyanate Chemical compound [S-]C#N.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UHDPBLMLEMNPKP-UHFFFAOYSA-M 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- LOEUPVXIWVJADW-UHFFFAOYSA-N 2-aminoethanol;1h-pyridin-2-one Chemical compound NCCO.O=C1C=CC=CN1 LOEUPVXIWVJADW-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- ZSNLEVJATWJBLU-UHFFFAOYSA-N 2-tert-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(C(C)(C)C)(OC)C(=O)C1=CC=CC=C1 ZSNLEVJATWJBLU-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- DDGPBVIAYDDWDH-UHFFFAOYSA-N 3-[dodecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O DDGPBVIAYDDWDH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- LDMRLRNXHLPZJN-UHFFFAOYSA-N 3-propoxypropan-1-ol Chemical compound CCCOCCCO LDMRLRNXHLPZJN-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- IELOKBJPULMYRW-IKTKBOKFSA-N 4-oxo-4-[[(2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OC(CCC(O)=O)=O IELOKBJPULMYRW-IKTKBOKFSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000130781 Arnebia Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- 241000825839 Cantinoa mutabilis Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 235000003198 Cynara Nutrition 0.000 description 1
- 241000208947 Cynara Species 0.000 description 1
- 244000309023 Cynara scolymus Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 235000013939 Malva Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- 244000052585 Rosa centifolia Species 0.000 description 1
- 235000016588 Rosa centifolia Nutrition 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- QEKBRBCVWVLFHH-QAKUKHITSA-L Tocopherol calcium succinate Chemical compound [Ca+2].[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C.[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C QEKBRBCVWVLFHH-QAKUKHITSA-L 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000004110 Zinc silicate Substances 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- TXGSMRRWACWHFZ-MVIDNBQJSA-N [(2r,3s,4s)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-tris(pyridine-3-carbonyloxy)pentyl] pyridine-3-carboxylate Chemical compound O([C@@H](CN1C=2C(C(NC(=O)N=2)=O)=NC=2C=C(C(=CC=21)C)C)[C@H](OC(=O)C=1C=NC=CC=1)[C@@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 TXGSMRRWACWHFZ-MVIDNBQJSA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- VVNANPHBTSDUIH-UHFFFAOYSA-N [5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl acetate Chemical compound CC(=O)OCC1=CN=C(C)C(O)=C1CO VVNANPHBTSDUIH-UHFFFAOYSA-N 0.000 description 1
- OOHTWBUKWQKKEE-UHFFFAOYSA-N [6-(diethylamino)-6-hydroxy-7-oxo-7-phenylheptyl] benzoate Chemical compound C=1C=CC=CC=1C(=O)C(O)(N(CC)CC)CCCCCOC(=O)C1=CC=CC=C1 OOHTWBUKWQKKEE-UHFFFAOYSA-N 0.000 description 1
- GNKTZDSRQHMHLZ-UHFFFAOYSA-N [Si].[Si].[Si].[Ti].[Ti].[Ti].[Ti].[Ti] Chemical compound [Si].[Si].[Si].[Ti].[Ti].[Ti].[Ti].[Ti] GNKTZDSRQHMHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000006359 acetalization reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- QVFOGJXHRGAFSH-UHFFFAOYSA-N acetic acid;1-dodecoxydodecane Chemical compound CC(O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC QVFOGJXHRGAFSH-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940063656 aluminum chloride Drugs 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960002298 aminohydroxybutyric acid Drugs 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IZJRISIINLJVBU-UHFFFAOYSA-N beta-Butoxyethyl nicotinate Chemical compound CCCCOCCOC(=O)C1=CC=CN=C1 IZJRISIINLJVBU-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- PTIXVVCRANICNC-UHFFFAOYSA-N butane-1,1-diol;hexanedioic acid Chemical compound CCCC(O)O.OC(=O)CCCCC(O)=O PTIXVVCRANICNC-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- JIHMVMRETUQLFD-UHFFFAOYSA-N cerium(3+);dioxido(oxo)silane Chemical compound [Ce+3].[Ce+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JIHMVMRETUQLFD-UHFFFAOYSA-N 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 229940059402 eriobotrya japonica leaf extract Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- ZMPFVMSHKCGRFH-UHFFFAOYSA-N hexyl 3-(diethylamino)-2-hydroxybenzoate Chemical compound CCCCCCOC(=O)C1=CC=CC(N(CC)CC)=C1O ZMPFVMSHKCGRFH-UHFFFAOYSA-N 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940091554 lauryl peg-9 polydimethylsiloxyethyl dimethicone Drugs 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GUMSHIGGVOJLBP-SLRPQMTOSA-N methyl hesperidin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 GUMSHIGGVOJLBP-SLRPQMTOSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 1
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940088608 peg-9 polydimethylsiloxyethyl dimethicone Drugs 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- PYJBVGYZXWPIKK-UHFFFAOYSA-M potassium;tetradecanoate Chemical compound [K+].CCCCCCCCCCCCCC([O-])=O PYJBVGYZXWPIKK-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 1
- PFIPZKASKUWLHH-UHFFFAOYSA-N pyridoxamine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CN)=C1O PFIPZKASKUWLHH-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940074113 rosa multiflora fruit extract Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940079781 sodium cocoyl glutamate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- HWCHICTXVOMIIF-UHFFFAOYSA-M sodium;3-(dodecylamino)propanoate Chemical compound [Na+].CCCCCCCCCCCCNCCC([O-])=O HWCHICTXVOMIIF-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 229940069762 swertia japonica extract Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 229940118827 zinc phenolsulfonate Drugs 0.000 description 1
- XSMMCTCMFDWXIX-UHFFFAOYSA-N zinc silicate Chemical compound [Zn+2].[O-][Si]([O-])=O XSMMCTCMFDWXIX-UHFFFAOYSA-N 0.000 description 1
- 235000019352 zinc silicate Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- BOVNWDGXGNVNQD-UHFFFAOYSA-L zinc;2-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=CC=C1S([O-])(=O)=O.OC1=CC=CC=C1S([O-])(=O)=O BOVNWDGXGNVNQD-UHFFFAOYSA-L 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/411—Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明目的在于研究大气污染物质如何影响免疫反应和皮肤的屏障功能,提供有效改善大气污染物质所致的皮肤障碍的组合物。提供含有至少1种以上IL‑8表达抑制物的、用于改善大气污染物质所致的皮肤障碍的组合物。另外,提供含有至少1种以上水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质的、用于改善大气污染物质所致的皮肤障碍的组合物。另外,提供含有至少1种以上氧化应激抑制物的、用于改善大气污染物质所致的皮肤障碍的组合物。另外,提供含有至少1种以上IL‑33表达抑制物的、用于改善大气污染物质所致的皮肤障碍的组合物。
Description
本申请是申请号为201880067463.6、申请日为2018年10月22日、发明名称为“皮肤障碍改善用组合物”的发明申请的分案申请。
技术领域
本发明涉及皮肤障碍改善用组合物。更详细而言,涉及用于改善大气污染物质所致的皮肤障碍的组合物。
背景技术
随着产业的发展、人口的增加,在世界上大气污染成为严重的问题。据报道,存在PM2.5、尾气、房屋灰尘等各种大气污染物质的情况下,目前会导致哮喘、支气管炎之类的呼吸器官疾病、心脏病等循环系统疾病。
近年来新关注大气污染物质参与特应性皮炎、过敏所致的皮肤疾病。专利文献1中提出了一种以胡颓子科沙棘属的提取物为有效成分的起因为气溶胶粒子的皮肤炎症的抑制剂。另外,专利文献2中提出了保护皮肤免受大气污染物质等的影响为目的的、含有规定量的偏硅酸铝酸镁以及甲氧基肉桂酸辛酯和/或二乙氨基羟苯甲酰基苯甲酸己酯的护肤化妆品。
现有技术文献
专利文献
专利文献1:日本特开2016-216366号公报
专利文献2:日本特开2017-105825号公报。
发明内容
然而,大气污染物质与皮肤疾病的关系尚不清楚的地方很多,有必要阐明分子机制,并提出对策。
因此,本发明的目的在于提供一种有效地改善大气污染物质所致的皮肤障碍的组合物。
为了解决上述课题,本发明人等反复进行了深入的研究,其结果,由于大气污染物质,发现了特定的基因表达的促进或降低、氧化应激的上升、紧密连接的障碍等,从而完成本发明。
即,本发明提供下述的组合物。
[1]一种用于改善大气污染物质所致的皮肤障碍的组合物,含有至少1种以上的IL-8表达抑制物。
[2]根据[1]所述的组合物,其中,上述皮肤障碍为皮肤炎症和/或瘙痒。
[3]根据[1]或[2]所述的组合物,其中,上述IL-8表达抑制物为选自透明质酸及其盐、透明质酸的衍生物及其盐、朝鲜蓟提取物、氨甲环酸及其盐、维氏熊竹叶提取物、山茶提取物、蔷薇提取物、紫苏提取物、黄芩提取物、甘草提取物、甘茶提取物、芦荟叶提取物、野蔷薇果实提取物、黄连提取物、枇杷叶提取物、樱叶提取物、迷迭香叶提取物、紫草叶提取物、鼠尾草叶提取物、百里香提取物、胡萝卜根提取物、尿囊素、乌芬那酯、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯以及胆固醇类中的1种或2种以上。
[4]一种用于改善大气污染物质所致的皮肤障碍的组合物,至少含有1种以上的水闸蛋白(Claudin)表达促进物质和/或闭锁蛋白(Occuludin)表达促进物质。
[5]根据[4]所述的组合物,其中,上述皮肤障碍是因皮肤屏障功能的降低和/或不成熟引起的。
[6]根据[4]或[5]所述的组合物,其中,上述水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质为选自橘果皮提取物、越橘叶提取物、白柳皮提取物、山金车提取物、明日叶提取物、薏苡提取物、银杏叶提取物、姜黄提取物、野蔷薇提取物(玫瑰果提取物)、黄芩提取物、魁蒿提取物、洋甘菊提取物、紫苏叶提取物、桃子提取物、香蜂花(Melissa)提取物、薰衣草提取物以及N-月桂酰-L-谷氨酸与L-赖氨酸的缩合物的钠盐中的1种或2种以上。
[7]一种用于改善大气污染物质所致的皮肤障碍的组合物,至少含有1种以上的氧化应激抑制物。
[8]根据[7]所述的组合物,其中,上述皮肤障碍为选自肌肤的皱纹、斑点、痤疮以及松弛中的至少1种。
[9]根据[7]或[8]所述的组合物,其中,上述氧化应激抑制物为选自黄芩提取物、越橘提取物、水解蜂王浆、葵花油、苦薄荷、甘油葡糖苷、木天蓼提取物、烟酰胺、糖原、积雪草提取物、锦葵提取物、鱼腥草提取物、印度楝提取物、藻类提取物、黄柏提取物、抗坏血酸、银杏叶提取物、甘茶提取物、绿茶提取物、芦荟叶提取物、芙蓉花提取物、紫苏叶提取物、迷迭香叶提取物、鼠尾草叶提取物、柑橘提取物、洋甘菊提取物、甘草提取物、朝鲜蓟提取物以及桉树提取物中的1种或2种以上。
[10]一种用于改善大气污染物质所致的皮肤障碍的组合物,含有至少1种以上的IL-33表达抑制物。
[11]根据[10]所述的组合物,其中,上述皮肤障碍为选自瘙痒、湿疹、皮肤炎、皮疹、荨麻疹以及糜烂中的至少1种。
[12]根据[10]或[11]所述的组合物,其中,上述IL-33表达抑制物为选自尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明及其盐、透明质酸及其盐、透明质酸的衍生物及其盐、氯化镁、胆固醇类、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及乌芬那酯中的1种或2种以上。
[13]根据[1]~[12]中任一项所述的组合物,其中,上述大气污染物质为选自汽车尾气、城市大气粉尘、花粉以及砂尘中的至少1种。
根据本发明,能够在产生大气污染物质所致的皮肤障碍的情况下有效地改善症状。
附图说明
图1是表示试验例1中的、NHEK(Human Epidermal Keratinocyte)的大气污染物质所致的细胞毒性评价的结果的图表。将10μg/mL、25μg/mL、50μg/mL或250μg/mL、500μg/mL、1000μg/mL的大气污染物质添加到NHEK。从添加大气污染物质起24小时后,利用Hoechst染色,使细胞可视化,并用ImageXpress测定细胞数。结果以平均±标准偏差(n=3)表示。
图2是表示试验例2中的、大气污染物质对皮肤的影响评价(基因表达解析)的结果的图表。将10μg/mL、25μg/mL、50μg/mL或250μg/mL、500μg/mL、1000μg/mL的大气污染物质添加到NHEK。从添加大气污染物质起24小时后,从细胞提取总RNA。通过qRT-PCR测定IL-1β、IL-6、IL-8、IL-33、MMP-1和MMP-9的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特测试(Dunnett's test),通过与对照组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图3是表示试验例3中的、大气污染物质对皮肤的影响评价(氧化应激)的结果的图表。将10μg/mL、25μg/mL、50μg/mL或250μg/mL、500μg/mL、1000μg/mL的大气污染物质添加到NHEK。从添加大气污染物质起24小时后,用CellROX(注册商标)Green Reagent以及ImageExpress测定细胞的氧化应激。结果以平均±标准偏差(n=3)表示。P值通过邓奈特测试,利用与对照组的比较,以***P<0.001表示。
图4是表示试验例4中的、大气污染物质所致的IL-8表达量的评价的结果的图表。将10μg/mL、25μg/mL、50μg/mL、或者250μg/mL、500μg/mL、1000μg/mL的大气污染物质添加到NHEK。从添加大气污染物质起24小时后,通过ELISA测定从NHEK向培养基分泌的IL-8水平,利用其细胞数进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与对照组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图5是表示试验例5中的、大气污染物质对屏障功能的影响评价(1)的结果的图表。NHEK在培养皿中汇合后,为了分化诱导在2mM Ca2+的条件下培养。分化诱导6天后,在2mMCa2+的条件下添加50μg/mL或1000μg/mL的大气污染物质。屏障功能通过TER评价。结果以平均±标准偏差(n=3)表示。P值通过学生t检验(Student's t test),利用与对照组的比较,以*P<0.05表示。
图6是表示试验例6中的、大气污染物质对屏障功能的影响评价(2)的结果的图表。NHEK在培养皿中汇合后,在2mM Ca2+的条件下将50μg/mL或1000μg/mL的大气污染物质添加到细胞。屏障功能通过TER评价。结果以平均±标准偏差(n=3)表示。P值通过学生t检验(Student’st test),利用与对照组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图7是表示试验例7中的、阐明大气污染物质所致的屏障形成机理降低作用机理的结果的图表。NHEK在培养皿中汇合后,在2mM Ca2+的条件下将50μg/mL或者1000μg/mL的大气污染物质添加到细胞。分化诱导6天后,从细胞提取总RNA。通过qRT-PCR测定CLDN1和OCLN的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过学生t检验(Student’s t test),利用与对照组的比较,以**P<0.01、***P<0.001表示。
图8是表示试验例8中的、抑制UA所致的IL-8的活化的材料探索的结果的图表。将候补化合物添加到NHEK。从候补化合物的添加起24小时后,将UA50μg/mL和候补化合物添加到NHEK。从UA的添加起24小时后,通过ELISA测定从NHEK向培养基分泌的IL-8水平,利用其细胞数进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与UA50μg/mL组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图9是表示试验例9中的、改善UA所致的屏障功能降低的材料探索的结果的图表。NHEK在培养皿中汇合后,在2mM Ca2+的条件下将50μg/mL的UA和候补化合物添加到细胞。屏障功能通过TER评价。结果以平均±标准偏差(n=3)表示。P值通过学生t检验(Student’s ttest),利用与UA50μg/mL组的比较,以*P<0.05、**P<0.01表示。
图10是表示试验例10中的、柑橘果皮提取物的屏障功能改善机理的阐明结果的图表。NHEK在培养皿中汇合后,在2mM Ca2+的条件下将50μg/mL的UA和候补化合物添加到细胞中。分化诱导4天后和5天后,从细胞提取总RNA。通过qRT-PCR测定CLDN1的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过学生t检验(Student’st test),利用与UA50μg/mL组的比较,以**P<0.01表示。
图11是表示试验例11中的、二维皮肤模型中的大气污染物质介由表皮对真皮的影响评价的结果的图表。将25μg/mL、50μg/mL的大气污染物质添加到NHEK。从添加大气污染物质起24小时后,回收上清液,通过过滤器过滤从上清液中除去大气污染物质之后,添加到NHDF(Human dermal fibroblast)中。从上清液的添加起4天后,利用ELISA测定从NHDF向培养基分泌的MMP1和MMP3水平,利用其细胞数进行标准化。结果以平均±标准偏差(n=3)表示。P值通过学生t检验(Student’st test),利用与上清的对照组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图12是表示试验例12中的、三维皮肤模型中的大气污染物质介由表皮对真皮的影响评价的结果的图表。将50μg/mL、500μg/mL的大气污染物质添加到EFT400的表皮上。从添加大气污染物质起3天后,通过ELISA测定向培养基中分泌的MMP1和MMP3水平,利用其细胞数进行标准化。结果以平均±标准偏差(n=3)表示。P值通过学生t检验(Student’st test)或邓奈特检验,利用与对照组的比较,以*P<0.05表示。
图13是表示试验例13中的、大气污染物质对斑点的影响评价的结果的图表。将10μg/mL、25μg/mL、50μg/mL的大气污染物质添加到NHEK。从添加大气污染物质起24小时后,从细胞提取总RNA。通过qRT-PCR测定PTGS2的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与对照组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图14是表示试验例14中的、二维皮肤模型中的大气污染物质介由表皮对黑色素细胞的影响评价的结果的图表。将50μg/mL的UA添加到NHEK。从UA的添加起24小时后,回收上清液,通过过滤器过滤从上清液中除去UA后,添加到NHEM(Human epidermal meranocyte)。从上清的添加起24小时后,从细胞提取总RNA。通过qRT-PCR测定TYR的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。
图15是表示试验例15中的、三维皮肤模型中大气污染物质介由表皮对黑色素细胞的影响评价的结果的图表。将500μg/mL、1000μg/mL的大气污染物质添加到MEL300A。从添加大气污染物质起24小时后,从细胞提取总RNA。通过qRT-PCR测定PTGS2和TYR的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与对照组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图16是表示试验例16中的、抑制大气污染物质所致的氧化应激的材料探索的结果的图表。将候补化合物添加到NHEK。从候补化合物的添加起24小时后,将50μg/mL的UA和候补化合物添加到NHEK。从添加大气污染物质起24小时后,用CellROX(注册商标)GreenReagent以及ImageExpress测定细胞的氧化应激。结果以平均±标准偏差(n=3)表示。
图17是表示试验例17中的、抑制大气污染物质所致的MMP1的材料探索的结果的图表。将候补化合物添加到NHEK。从候补化合物的添加起24小时后,将50μg/mL的UA和候补化合物添加到NHEK。从UA的添加起24小时后,利用ELISA测定从NHEK向培养基分泌的MMP1水平,利用其细胞数进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与UA50μg/mL组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图18是表示试验例18中的、抑制大气污染物质所致的IL-33的表达增加的材料探索的结果的图表。将2mg/mL的CP和候补化合物添加到NHEK。从CP的添加起6小时后,通过qRT-PCR测定IL-33的mRNA表达,利用同时测定的GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与CP 2mg/mL(对照)组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
图19是表示试验例19中的、抑制大气污染物质所致的IL-33的表达增加的材料探索的结果的图表。将100μg/mL的GKD和候补化合物添加到NHEK。从GKD的添加起24小时后,通过qRT-PCR测定IL-33的mRNA表达,利用同时测定的GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与GKD 100μg/mL(对照)组的比较,以*P<0.05、**P<0.01、***P<0.001表示。
具体实施方式
[皮肤障碍改善用组合物]
一个实施方式中,本发明的皮肤障碍改善用组合物含有至少1种以上的IL-8表达抑制物。另外,本发明的皮肤障碍改善用组合物特别适于改善大气污染物质所致的皮肤障碍。
本说明书中,IL-8表达抑制物只要是在体外、离体或体内能够抑制IL-8的基因表达或蛋白质表达的物质就没有特别限制。IL-8的表达抑制率是在IL-8的基因表达或蛋白质表达中相对于大气污染物质存在下且IL-8表达抑制物不存在下的条件可以至少为1%,优选为2%,更优选为5%,进一步优选为10%。IL-8的基因表达或者蛋白质表达的测定方法可以通过公知的方法测定,例如如实施例进行说明的那样,能够通过使用IL-8特异性探针的实时PCR法对IL-8的基因表达进行定量,能够通过使用IL-8特异性抗体的ELISA法对IL-8的蛋白质表达进行定量。
作为IL-8表达抑制物,只要起到本发明的效果,没有特别限制,可举出透明质酸及其盐、透明质酸的衍生物及其盐、朝鲜蓟提取物、氨甲环酸及其盐、维氏熊竹叶提取物、山茶提取物、蔷薇提取物、紫苏提取物、黄芩提取物、甘草提取物、甘茶提取物、芦荟叶提取物、野蔷薇果实提取物、黄连提取物、枇杷叶提取物、樱叶提取物、迷迭香叶提取物、紫草叶提取物、鼠尾草叶提取物、百里香提取物、胡萝卜根提取物、尿囊素、乌芬那酯、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、胆固醇类等。IL-8表达抑制物可以组合1种或2种以上使用。IL-8表达抑制物可以使用合成品,也可以使用市售品。
作为IL-8表达抑制物,从显著起到本发明的效果的观点考虑,优选为选自蔷薇提取物、透明质酸及其盐、透明质酸的衍生物及其盐、朝鲜蓟提取物、氨甲环酸及其盐、尿囊素、乌芬那酯、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及胆固醇类中的至少1种。
上述的IL-8表达抑制物中,透明质酸是由葡萄糖醛酸(GlcUA)与N-乙酰氨基葡萄糖(GlcNAc)结合而成的GlcUA-GlcNAc的基本结构(重复单元)构成的聚合物,是发挥保湿作用的公知的高分子化合物。
作为透明质酸的盐,只要是医药上、药理学或生理学被允许就没有特别限制。作为透明质酸的盐,例如可举出与有机碱的盐、与无机碱的盐。
作为甘草酸的盐,只要是药理学(制药上)或生理学被允许就没有特别限制。作为甘草酸的盐,优选为甘草酸单铵、甘草酸二钾。
作为与有机碱的盐,例如可举出与甲胺、三乙胺、三乙醇胺、吗啉、哌嗪、吡咯烷、三吡啶、甲基吡啶等有机胺的盐等。作为与无机碱的盐,例如可举出铵盐;钠、钾等碱金属盐;钙、镁等碱土类金属盐;与铝等金属的盐等。
对透明质酸及其盐的来源没有特别限制,例如可以从鸡冠得到,另外也可以来自微生物,并且还可以是合成品。其中,优选来自微生物的透明质酸(生物透明质酸)及其盐或它们的衍生物。
作为本发明中使用的透明质酸及其盐的粘均分子量,没有特别限制,可举出例如为0.01万~500万,优选为0.1万~400万,更优选为1万~300万,进一步优选为10万~250万,特别优选为50万~200万,最优选为100万~170万的范围。这里,粘均分子量可以通过公知的测定方法求出。具体而言,将透明质酸或其盐(干燥物)溶解于0.2M氯化钠溶液,利用乌氏粘度计求出30±0℃的特性粘度(η),基于Laurent式(η(特性粘度)=3.6×10-4·M0.78:这里M为粘均分子量)计算粘均分子量。特性粘度(η)的测定根据第17改正日本药典的一般试验法粘度测定法第1法:毛细管粘度计法而实施。
作为透明质酸及其盐,也可以使用透明质酸低聚糖。本说明书中,透明质酸低聚糖是指含有1单元的葡萄糖醛酸(GlcUA)和N-乙酰氨基葡萄糖(GlcNAc)结合而成的GlcUA-GlcNAc基本结构(重复单元)的2糖以上的物质。透明质酸低聚糖优选为将1单元~10单元的基本结构的重复单元结合而成的物质,也可以是它们的盐或衍生物。作为透明质酸低聚糖,没有限定,可举出4糖(HA4)、6糖(HA6)、8糖(HA8)、10糖(HA10)、12糖(HA12)等。例如4糖(HA4)的透明质酸低聚糖是指含有2单元的基本结构的重复单元。
作为透明质酸的衍生物及其盐,可举出透明质酸等的羟基、羧基等发生醚化、酯化、酰胺化、乙酰化、乙缩醛化等而得到的衍生物、利用透明质酸酶等酶部分分解而得的透明质酸分解物、通过酸水解部分分解而得的透明质酸水解物、通过交联剂交联而得的交联透明质酸等。
透明质酸及其盐以及透明质酸的衍生物及其盐中,例如可以使用透明质酸低聚糖、水解透明质酸或低分子透明质酸及其盐以及它们的衍生物,其中更优选为4糖(HA4)的透明质酸低聚糖。
透明质酸及其盐以及透明质酸的衍生物及其盐可以通过以往公知的方法制造。另外,透明质酸及其盐和透明质酸的衍生物及其盐多种多样,也可以将它们的市售品用于本发明。作为这些市售品,例如可举出透明质酸HA-LQ-RS、透明质酸HA-LQ60、透明质酸钠HA-QA、HYALO-OLIGO、HYALOVEIL、HYALO-ZINC(以上,Kewpie公司制),生物透明质酸钠HA12NB、生物透明质酸钠HA20N、乙酰化透明质酸钠(以上,资生堂社制),透明质酸低聚糖4糖(HA4)、6糖(HA6)、8糖(HA8)、10糖(HA10)、12糖(HA12)(以上,Cosmo Bio公司),Oligo-HA4、Oligo-HA6(以上,SIGMA公司),透明质酸FCH-120、透明质酸FCH-121C(以上,Kikkoman Biochemifa公司制),透明质酸FCH-SU(Kibun Food Chemifa公司制),HYALU-CAGE SYSTEM(IRA srl公司制)等。
上述的IL-8表达抑制物中,朝鲜蓟提取物没有限定,是通过对朝鲜蓟(别名菜蓟)实施基于提取溶剂的提取处理而得的提取物。朝鲜蓟(学名Cynara scolymus L.)是属于菊科菜蓟属的多年草本植物。
本说明书中,使用植物的提取物(也称为植物的提取物)的情况下,作为提取溶剂,可以适当使用水(包括热水)、甲醇、乙醇、异丙醇、乙二醇、1,3-丁二醇、甘油等醇类、乙酸乙酯等酯类、丙酮、甲乙酮等酮类、乙腈等腈类、二乙醚、四氢呋喃等醚类、戊烷、己烷、环戊烷、环己烷等饱和烃类、甲苯等芳香族烃类、二氯甲烷、氯仿等卤代烃类、其他的二甲基甲酰胺、二甲基亚砜等有机溶剂(全部可以含水)等,可以是1种或2种任意的混合液。这些溶剂中,优选为水、乙醇、1,3-丁二醇或它们的混合溶液。本说明书中记载的提取物可以从各种原料品公司得到,它们通常以包含提取溶剂、稀释溶剂等在内的形态进行销售。以下,提取物量是指包括干燥固体成分和这些溶剂等在内的量。
本说明书中,植物的提取物可以是从植物的全草或必要部位(花、头状花、花芽、花蕾、花穗、叶、枝、枝叶、根茎、根皮、根、树皮、果实、果皮、荚果、种子等)提取的粗提物或进一步将其精制处理而成的物质,也可以是浓缩处理的物质,也可以是通过合成得到的物质,还可以使用市售品。作为得到植物的提取物的方法,没有特别限定,可采用通常的提取法、精制方法、浓缩方法、合成方法、干燥粉末化方法等。
使用朝鲜蓟提取物作为植物的提取物时,优选为选自全草、花、叶、茎和根中的至少1种的提取物,更优选为叶的提取物。朝鲜蓟提取物可以使用市售品。
使用蔷薇提取物作为植物的提取物时,优选为选自全草、果实、花、叶、茎和根中的至少1种的提取物,更优选为果实和/或叶的提取物,进一步优选为果实的提取物。蔷薇提取物可以使用市售品。另外,作为蔷薇提取物,有刺梨提取物、香水月季(Rosa odorata)提取物、硕苞蔷薇(Rosa bracteata)提取物、百叶蔷薇(Rosa centifolia)提取物、突厥蔷薇(Rosa damascena)提取物、野蔷薇提取物等,优选刺梨提取物。
本说明书中,植物的提取物可以使用液状的物质,也可以根据需要通过进行减压干燥、冻结干燥、喷雾干燥等干燥处理而将液体成分减少或除去而形成浓缩液状、半固体形状、固体形状、或粉末状的物质。
氨甲环酸是也被称为反式-4-(氨基甲基)环己烷-1-羧酸的化合物,可以通过公知的方法合成,还可以作为市售品得到。
氨甲环酸可以作为其衍生物使用。作为其衍生物,可举出氨甲环酸十六烷基酯、氨甲环酸甲基酰胺、氨甲环酸乙基酰胺等。
氨甲环酸可以作为其盐使用。作为氨甲环酸的盐,只要药理学(制药上)或生理学被允许,则没有特别限制。作为氨甲环酸的盐,例如可举出钠盐、钾盐等碱金属盐;钙盐、镁盐等碱土类金属盐;锌盐;铁盐;铵盐;与精氨酸、赖氨酸、组氨酸、鸟氨酸等碱性氨基酸的盐;与单乙醇胺、二乙醇胺、三乙醇胺等胺的盐等。作为氨甲环酸的盐,其中,优选钠盐、钾盐、三乙醇胺盐、精氨酸盐,更优选钠盐。“盐”可以包含盐的溶剂合物或水合物。
尿囊素、乌芬那酯、甘草次酸及其盐、甘草次酸十八酯为公知的化合物,可以通过公知的方法合成,也可以作为市售品得到。
作为胆固醇类及其盐,例如可举出胆固醇、豆甾醇、羊毛甾醇、麦角甾醇、或它们的盐等。
IL-8表达抑制物中,含有提取物时,其提取物量可以根据其他的配合成分的种类和含量、组合物的制剂形态等适当地设定,但相对于组合物总量,没有特别限定,相对于组合物总量,优选为0.00001~10质量%,更优选为0.0001~5质量%,进一步优选为0.001~2质量%,特别优选为0.01~1质量%。应予说明,使用提取物时,作为干燥固体成分含量,相对于提取物总量,优选为0.0005~30质量%,更优选为0.001~20质量%,特别优选为0.01~10质量%。
作为IL-8表达抑制物,含有透明质酸及其盐和透明质酸的衍生物及其盐时,透明质酸及其盐和透明质酸的衍生物及其盐的单独的含量没有特别限定,例如可以为0.0001~5质量%,优选为0.001~1质量%,更优选为0.005~0.5质量%,进一步优选为0.01~0.1质量%。
作为IL-8表达抑制物,含有甘草酸及其盐时,甘草酸及其盐的单独的含量没有特别限定,例如可以为0.0001~10质量%,优选为0.001~5质量%,更优选为0.005~2质量%,进一步优选为0.01~1质量%。
作为IL-8表达抑制物,含有氨甲环酸及其盐时,氨甲环酸及其盐的单独的含量没有特别限定,例如可以为0.001~10质量%,优选为0.005~7质量%,更优选为0.01~5质量%,进一步优选为1~3质量%。
作为IL-8表达抑制物,含有尿囊素时,尿囊素的单独的含量没有特别限定,例如可以为0.001~10质量%,优选为0.002~5质量%,更优选为0.01~3质量%,进一步优选为0.2~1质量%。
作为IL-8表达抑制物,含有乌芬那酯时,乌芬那酯的单独的含量没有特别限定,例如可以为0.00001~10质量%,优选为0.0001~5质量%,更优选为0.01~7质量%,进一步优选为1~5质量%。
作为IL-8表达抑制物,含有甘草次酸及其盐或甘草次酸十八酯时,甘草次酸及其盐或者甘草次酸十八酯的单独的含量没有特别限定,例如可以为0.00001~10质量%,优选为0.0001~5质量%,更优选为0.01~3质量%,进一步优选为0.1~1质量%。
作为IL-8表达抑制物,含有胆固醇类时,胆固醇类的单独的含量没有特别限定,例如可以为0.001~20质量%,优选为0.002~10质量%,更优选为0.01~8质量%,进一步优选为0.05~5质量%。
另外,其它的实施方式中,本发明的皮肤障碍改善用组合物含有至少1种以上的水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质。
本说明书中,水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质只要是在体外、离体或体内能够促进水闸蛋白和/或闭锁蛋白的基因表达或蛋白质表达的物质就没有特别限制。水闸蛋白和/或闭锁蛋白的表达促进率在水闸蛋白和/或闭锁蛋白的基因表达或蛋白质表达中,相对于大气污染物质存在下且水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质不存在下的条件至少为1%即可,优选为2%,更优选为5%,进一步优选为10%。水闸蛋白和/或闭锁蛋白的基因表达或蛋白质表达的测定方法可以通过公知的方法测定,例如如实施例说明那样,能够通过使用水闸蛋白或闭锁蛋白特异性探针的实时PCR法对水闸蛋白或闭锁蛋白的基因表达进行定量。
水闸蛋白、闭锁蛋白是膜蛋白质,构成相邻的上皮细胞间的紧密连接。
作为水闸蛋白,可以为屏障型水闸蛋白(水闸蛋白-1、水闸蛋白-4、水闸蛋白-5、水闸蛋白-7、水闸蛋白-11、水闸蛋白-14、水闸蛋白-18、水闸蛋白-19等),也可以为通道型水闸蛋白(水闸蛋白-2、水闸蛋白-7、水闸蛋白-10、水闸蛋白-15、水闸蛋白-16等)。
作为水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质,只要起到本发明的效果,就没有特别限制,可举出橘果皮提取物、越橘叶提取物、白柳皮提取物、山金车提取物、明日叶提取物、薏苡提取物、银杏叶提取物、姜黄提取物、野蔷薇提取物(玫瑰果提取物)、黄芩提取物、魁蒿提取物、洋甘菊提取物、紫苏叶提取物、桃子提取物、香蜂花提取物、薰衣草提取物以及N-月桂酰-L-谷氨酸与L-赖氨酸的缩合物的钠盐等。水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质可以1种或组合2种以上使用。水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质可以使用合成品,也可以使用市售品。
作为水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质,从显著起到本发明的效果的观点考虑,优选为提取了橘属的果皮的提取物(以下,橘果皮提取物),更优选为陈皮提取物。
水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质中,橘果皮提取物没有限定,是通过对温州蜜桔Citrus unshiu Markowicz或者柑橘Citrus reticulate Blanco(Rutaceae)的成熟果皮实施基于提取溶剂的提取处理而得的提取物。虽然没有限定,但从显著起到本发明的效果的观点考虑,橘果皮提取物优选为来自柑橘的成熟果皮。
使用橘果皮提取物作为水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质时,作为提取溶剂,可适当使用水(包括热水)、甲醇、乙醇、异丙醇、乙二醇、1,3-丁二醇、甘油等的醇类、乙酸乙酯等酯类、丙酮、甲乙酮等酮类、乙腈等腈类、二乙醚、四氢呋喃等醚类、戊烷、己烷、环戊烷、环己烷等饱和烃类、甲苯等芳香族烃类、二氯甲烷、氯仿等卤代烃类、其他的二甲基甲酰胺、二甲基亚砜等有机溶剂(全部可以含水)等,可以为1种或2种任意的混合液。这些溶剂中,优选水、乙醇、1,3-丁二醇或它们的混合溶液。
橘果皮提取物可以是从温州蜜桔或柑橘的成熟的果皮提取的粗提取物或进一步将其进行精制处理而得的物质,也可以是将其浓缩处理而得的物质,还可以是通过合成而得到的物质,也可以使用市售品。作为得到橘果皮提取物的方法,没有特别限定,采用通常的提取法、精制方法、浓缩方法、合成方法、干燥粉末化方法等。另外,使用陈皮提取物作为橘果皮提取物时,可以是满足收载于第十七次修订日本药典的项目的物质。
水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质的总含量根据其他的配合成分的种类和含量、组合物的制剂形态等适当地设定,相对于组合物总量,优选为0.00001质量%以上,更优选为0.0001质量%以上,进一步优选为0.001质量%以上,特别是优选为0.01质量%以上。水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质的总含量相对于组合物总量,优选为10质量%以下,更优选为5质量%以下,进一步优选为2质量%以下,特别优选为1质量%以下。水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质的总含量没有特别限定,相对于组合物总量,优选为0.00001~10质量%,更优选为0.0001~5质量%,进一步优选为0.001~2质量%,特别优选为0.01~1质量%。此外,使用提取物时,作为干燥固体成分含量,相对于提取物总量,优选为0.0005~30质量%,更优选为0.001~20质量%,特别优选为0.01~10质量%。
另外,其它的实施方式中,本发明的皮肤障碍改善用组合物含有至少1种以上的氧化应激抑制物。
作为氧化应激抑制物,只要是能够在体外、离体或体内抑制MMP-1等氧化应激相关因子的功能的物质就没有特别限制。作为氧化应激抑制物,只要起到本发明的效果,没有特别限制,可举出黄芩提取物、越橘提取物、水解蜂王浆、葵花油、苦薄荷、甘油葡糖苷、木天蓼提取物、烟酰胺、糖原、积雪草提取物、锦葵提取物、鱼腥草提取物、印度楝提取物、藻类提取物、黄柏提取物、抗坏血酸、银杏叶提取物、甘茶提取物、绿茶提取物、芦荟叶提取物、芙蓉花提取物、紫苏叶提取物、迷迭香叶提取物、鼠尾草叶提取物、柑橘提取物、洋甘菊提取物、甘草提取物、朝鲜蓟提取物、桉树提取物等。氧化应激抑制物可以1种或组合2种以上使用。氧化应激抑制物可以使用合成品,也可以使用市售品。作为氧化应激抑制物使用植物的提取物时的提取方法等基于关于“IL-8表达抑制物”的上述说明。
使用黄芩提取物作为植物的提取物时,优选为选自全草、花、叶、茎和根中的至少1种的提取物,更优选为叶和/或根的提取物,进一步优选为根的提取物。黄芩提取物可以使用市售品。
使用越橘提取物作为植物的提取物时,优选为选自全草、果实、花、叶、茎和根中的至少1种的提取物,更优选为果实和/或叶的提取物,进一步优选为叶的提取物。越橘提取物可以使用市售品。
作为水解蜂王浆,只要可配合于食品、化妆品等,制造方法就没有特别限制。水解蜂王浆可以例如通过向蜂王浆中添加水和蛋白质分解酶,在加温和加压下反应而制造。水解蜂王浆也可以使用市售品。
作为葵花油,只要可配合于食品、化妆品等,制造方法没有特别限制。作为葵花油,优选为从葵花的种子提取的葵花油。葵花油可以使用市售品。
苦薄荷是以唇形科苦薄荷属植物为原料的提取物,优选为选自全草、花、叶、茎和根中的至少1种的提取物,更优选为花和/或叶的提取物,进一步优选为叶的提取物。苦薄荷可以使用市售品。
作为甘油葡糖苷,只要可配合于医药品、化妆品等,制造方法可以是合成、利用微生物的发酵法等。具体而言,可使用α体、β体、或它们的混合物中的任一种。甘油葡糖苷可使用市售品。
使用木天蓼提取物作为植物的提取物时,优选为选自全草、果实、花、叶、茎和根中的至少1种的提取物,更优选为果实和/或叶的提取物,进一步优选为果实的提取物。木天蓼提取物可以使用市售品。
作为糖原,只要可配合于医药品、化妆品等,制造方法没有特别限制。作为糖原,可举出来自扇贝、鲍鱼、牡蛎、贻贝、珍珠贝等贝类、牛、猪的肝脏等的动物性糖原,来自玉米、大麦、大米、马铃薯、木薯等的植物性糖原,优选为植物性糖原。这些糖原可以直接使用通过常法制备的天然物中含有的糖原,另外,也可以使用根据需要进行酶处理后经分离精制处理而得的糖原,另外可以使用市售品。
使用积雪草提取物作为植物的提取物时,优选为选自全草、果实、花、叶、茎和根中的至少1种的提取物,更优选为叶和/或茎的提取物,进一步优选为叶的提取物。积雪草提取物可以使用市售品。
使用锦葵提取物作为植物的提取物时,优选为选自全草、果实、花、叶、茎和根中的至少1种的提取物,更优选为花和/或叶的提取物,进一步优选为花的提取物。锦葵提取物可以使用市售品。
使用鱼腥草提取物作为植物的提取物时,优选为选自全草、果实、花、叶、茎和根中的至少1种的提取物,更优选为叶和/或茎的提取物,进一步优选为叶的提取物。鱼腥草提取物可以使用市售品。
使用印度楝提取物作为植物的提取物时,优选为选自全草、果实、花、叶、茎和根中的至少1种的提取物,更优选为叶和/或茎的提取物,进一步优选为叶的提取物。印度楝提取物可以使用市售品。
藻类提取物只要可配合于医药品、化妆品等,制造方法没有特别限制。藻类提取物以藻类为原料,优选为选自褐藻、红藻和绿藻中的至少1种的提取物,更优选为它们的混合提取物。可以使用市售品。
氧化应激抑制物中,含有提取物时,其提取物量根据其它配合成分的种类和含量、组合物的制剂形态等适当地设定,相对于组合物总量,没有特别限定,相对于组合物总量,优选为0.00001~10质量%,更优选为0.0001~5质量%,进一步优选为0.001~2质量%,特别优选为0.01~1质量%。应予说明,使用提取物时,作为干燥固体成分含量,相对于提取物总量,优选为0.0005~30质量%,更优选为0.001~20质量%,特别优选为0.01~10质量%。
含有水解蜂王浆作为氧化应激抑制物时,水解蜂王浆的单独的含量没有特别限定,例如可以为0.00001~1质量%,优选为0.00005~0.5质量%,更优选为0.0001~0.2质量%,进一步优选为0.001~0.1质量%。
含有甘油葡糖苷作为氧化应激抑制物时,甘油葡糖苷的单独的含量没有特别限定,例如可以为0.0001~10质量%,优选为0.001~5质量%,更优选为0.005~2质量%,进一步优选为0.01~1质量%。
含有烟酰胺作为氧化应激抑制物时,烟酰胺的单独的含量没有特别限定,例如可以为0.005~20质量%,优选为0.01~10质量%,更优选为0.05~5质量%,进一步优选为0.1~1质量%。
含有糖原作为氧化应激抑制物时,糖原的单独的含量没有特别限定,例如可以为0.001~10质量%,优选为0.003~5质量%,更优选为0.005~3质量%,进一步优选为0.01~1质量%。
含有抗坏血酸作为氧化应激抑制物时,抗坏血酸的单独的含量没有特别限定,例如可以为0.01~30质量%,优选为0.1~25质量%,更优选为1~20质量%,进一步优选为3~10质量%。
另外,其它的实施方式中,本发明的皮肤障碍改善用组合物含有至少1种以上的IL-33表达抑制物。
本说明书中,IL-33表达抑制物只要是在体外、离体或体内能够抑制IL-33的基因表达或蛋白质表达的物质就没有特别限制。IL-33的表达抑制率在IL-33的基因表达或蛋白质表达中,相对于大气污染物质存在下且IL-33表达抑制物不存在下的条件至少为1%即可,优选为2%,更优选为5%,进一步优选为10%。IL-33的基因表达或蛋白质表达的测定方法可以通过公知的方法测定,例如如实施例中说明的那样,可以通过使用IL-33特异性探针的实时PCR法对IL-33的基因表达进行定量。
作为IL-33表达抑制物,只要起到本发明的效果,没有特别限制,可举出尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明及其盐、透明质酸及其盐、透明质酸的衍生物及其盐、氯化镁、胆固醇类、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、乌芬那酯等。IL-33表达抑制物可以1种或组合2种以上使用。IL-33表达抑制物可以使用合成品,也可以使用市售品。这些成分中,尿囊素、透明质酸及其盐、透明质酸的衍生物及其盐、胆固醇类、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯的种类、含量等基于有关“IL-8表达抑制物”的上述说明。
作为苯海拉明的盐,只要药理学(制药上)或生理学被允许,就没有特别限制。作为苯海拉明的盐,优选为苯海拉明盐酸盐。
含有利多卡因作为IL-33表达抑制物时,利多卡因的单独的含量没有特别限定,例如可以为0.001~10质量%,优选为0.002~7质量%,更优选为0.01~5质量%,进一步优选为0.2~2质量%。
含有异丙基甲基苯酚作为IL-33表达抑制物时,异丙基甲基苯酚的单独的含量没有特别限定,例如可以为0.0001~10质量%,优选为0.001~7质量%,更优选为0.01~5质量%,进而优选为0.05~0.5质量%。
含有苯海拉明及其盐作为IL-33表达抑制物时,苯海拉明及其盐的单独的含量没有特别限定,例如可以为0.001~10质量%,优选为0.005~7质量%,更优选为0.01~5质量%,进一步优选为0.5~2质量%。
含有氯化镁作为IL-33表达抑制物时,氯化镁的单独的含量没有特别限定,例如可以为0.001~10质量%,优选为0.002~8质量%,更优选为0.005~5质量%,进一步优选为0.01~3质量%。
本说明书中,化合物的盐除了上述列举的物质之外,例如可例示与碱金属盐、碱土类金属盐、有机碱等的盐,可举出与钠、钾、钙、镁、铵、或者二乙醇胺、乙二胺等的盐。这些盐通过公知的方法将存在于化合物中等的例如羧基等基团变换为盐而得到。进而也可举出与氨、甲胺、二甲胺、三甲胺、二环己胺、三(羟甲基)氨基甲烷、N,N-双(羟基乙基)哌嗪、2-氨基-2-甲基-1-丙醇、乙醇胺、N-甲基葡萄糖胺、L-葡萄糖胺等胺的盐;或者与赖氨酸、δ-羟基赖氨酸、精氨酸等碱性氨基酸的盐等。另外,例如也可举出与盐酸、氢溴酸、硫酸、硝酸、磷酸等无机酸的盐;与甲磺酸、苯磺酸、对甲苯磺酸、乙酸、丙酸、酒石酸、富马酸、马来酸、苹果酸、草酸、琥珀酸、柠檬酸、苯甲酸、扁桃酸、肉桂酸、乳酸、乙醇酸、葡萄糖醛酸、抗坏血酸、烟酸、水杨酸等有机酸的盐;或者与天冬氨酸、谷氨酸等酸性氨基酸的盐等。
[用途]
本发明的皮肤障碍改善用组合物特别适于大气污染物质所致的皮肤障碍的改善。作为大气污染物质,例如可举出二氧化硫、二氧化氮、悬浮粒子状物质、光化学氧化剂、三氯乙烯等。此外,根据大气污染防止法(1968年),来自固定来源的排放受到限制的硫氧化物、氮氧化物、粉尘、镉、氯、铅、氯化氢、氟化氢等“烟雾”、作为从矿物质等堆积物飞散的“一般粉尘”、“特殊粉尘”的石棉、被确定为“特殊物质”的苯等。另外,来自移动来源的排出受到限制的一氧化碳、烃属于此类。近年来,也包括作为病房综合症的成因物质的甲醛等。另外,恶臭可被视为大气污染的一种形态,其成因物质也作为大气污染物质而举出。浮游粒状物质(Suspended Particulate Matter,SPM)是指在大气中悬浮的固体和液体粒子,根据粒子的大小分类(也被称为气溶胶粒子),也包括汽车尾气、城市大气粉尘和砂尘(黄沙等)。在环境标准中规定了粒子的大小为10μm以下的PM10、粒子的大小为2.5μm以下的微小粒状物质PM2.5。浮游粒状物质中除了包含碳成分、硝酸盐、硫酸盐、铵盐之外还可包含硅、钠、铝等无机元素等。另外,浮游粒状物质中也可以含有成为运输放射性铯等放射性物质的载体的物质。这里“黄沙”通常指从黄河流域和沙漠等由风带走的沙尘,是指粒子的大小为4μm附近的物质。本发明中,从对皮肤的作用的观点考虑,作为大气污染物质,选自二氧化硫、二氧化氮、浮游粒状物质、光化学氧化剂、三氯乙烯、烟雾、普通粉尘、特殊粉尘(石棉等)、特殊物质(苯等)、一氧化碳、烃、甲醛以及恶臭中的至少1种会对皮肤产生影响,特别是汽车尾气、城市大气粉尘、花粉或砂尘会对皮肤产生影响。
本说明书中,成为适用对象的皮肤只要是可与大气污染物质接触的部位即可,部位没有限制。虽然没有限定,但优选为向外界露出且可直接与大气污染物质接触的部位,更优选为脸、手、脚、头皮、脖子、胸部、背部等。另外,虽然没有限定,但从其它的观点考虑,优选为由于与大气污染物质接触且因衣服等的摩擦受到刺激可能加剧皮肤障碍的部位。另外,虽然没有限定,从其它的观点考虑,优选为由于与大气污染物质接触且因衣服等、毛发而湿度增加可能加剧皮肤障碍的部位。
本说明书中,本发明人等证实了通过使皮肤与大气污染物质接触,在表皮角化细胞中IL-8的表达在基因水平和蛋白质水平上亢进。基于该新的发现,含有至少1种以上的IL-8表达抑制物的组合物能够适当地用于大气污染物质所致的皮肤障碍改善用途。作为大气污染物质所致的皮肤障碍,可举出皮肤炎症、特应性皮炎、慢性荨麻疹、圆形脱毛症、皮肤瘙痒症(皮肤·肌肤的瘙痒)、皮疹、糜烂、晒伤、皱纹、斑点、痤疮、皮肤癌、肌肤粗糙、敏感肌肤等。虽然没有限定,但基于上述的机理,作为皮肤障碍,优选为大气污染物质所致的皮肤炎症,只要是伴随皮肤的炎症的症状、状态则可应用本发明。
另外,本说明书中,本发明人等证实了通过使皮肤接触大气污染物质(特别是汽车尾气或城市大气粉尘),在表皮角化细胞中水闸蛋白、闭锁蛋白的基因表达量降低。特别是新发现了在皮肤屏障功能为不成熟的情况或降低的情况下,导致皮肤屏障功能衰竭加速。基于该新的发现,含有至少1种以上的水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质的组合物可以适当地用于大气污染物质所致的皮肤障碍改善用途。虽然没有限定,但基于上述的机理,可适当地将本发明用于作为皮肤障碍的因皮肤屏障功能降低引起的皮肤疾病。本说明书中,皮肤屏障功能主要是指角质层保持水分的能力。皮肤屏障功能降低(或低、不成熟)的状态例如可举出低年龄的情况,优选为20岁以下,进一步优选为10岁以下,更优选为婴幼儿(0岁~7岁),特别优选为婴儿(0岁~2岁)。另外,皮肤屏障功能降低的状态例如可举出引起肌肤粗糙的情况、发生特应性皮炎的情况。皮肤屏障功能的测定如本说明书的实施例中详细所述,能够通过利用跨上皮电阻(TER)的测定来评价紧密连接的状态而进行。本发明也能够适当地用于皮肤屏障功能改善用途、紧密连接形成促进用途、紧密连接功能正常化/强化用途、细胞间粘接结构的形成促进用途、细胞间屏障功能正常化/强化用途、渗透屏障功能正常化/强化用途等。
并且,本说明书中,本发明人等证实了通过使皮肤与大气污染物质(特别是汽车尾气或城市大气粉尘)接触,氧化应激上升。基于已知由于氧化应激会导致皱纹、痤疮、斑点、肌肤的松弛或恶化,含有至少1种以上的氧化应激抑制物的组合物能够适当地用于大气污染物质所致的皮肤障碍改善用途。已知肌肤的氧化应激是由紫外线引起的,但根据本发明人等的新发现,推测根据肌肤的状态,即使利用防晒霜等保护肌肤免受紫外线照射,处于持续暴露于大气污染物质的环境时,也不足以减少肌肤的氧化应激。虽然没有限定,但基于上述的机理,适用于作为皮肤障碍的选自肌肤的皱纹、痤疮、斑点和松弛中的至少1种,更适用于选自皱纹、斑点和松弛中的至少1种,进一步适用于皱纹和/或斑点,特别适用于皱纹形成和/或斑点形成。另外,也可适用于因氧化应激引起的皮肤代谢的紊乱。
本说明书中,本发明人等通过使皮肤与大气污染物质接触,证实了在表皮角化细胞中IL-33的表达在基因水平上亢进。基于该新发现,含有至少1种以上的IL-33表达抑制物的组合物能够适当地用于大气污染物质所致的皮肤障碍改善用途。作为大气污染物质所致的皮肤障碍,可举出皮肤炎症、特应性皮炎、慢性荨麻疹、圆形脱毛症、皮肤瘙痒症(皮肤·肌肤的瘙痒)、皮疹、糜烂、晒伤、皱纹、斑点、痤疮、皮肤癌、肌肤粗糙、敏感肌肤等。虽然没有限定,但基于上述的机理,作为皮肤障碍,优选为大气污染物质所致的皮肤炎症,只要是伴随皮肤的炎症的症状、状态则可应用本发明。
另外,本发明适当地用于以下人群:欲阻挡大气污染物质的人、欲守护肌肤不受大气污染物质影响的人、欲屏蔽肌肤远离大气污染物质的人、欲将因大气污染物质而干燥的肌肤保湿的人、担心因大气污染引起瘙痒的人、敏感肌肤的人、欲调整皮肤的紧密连接的人、欲修复大气污染物质所致的反复肌肤粗糙的人、欲修复大气污染物质所致的日常肌肤粗糙的人、担心大气污染物质所致的肌肤的老化(老龄化)、氧化、皱纹、斑点、松弛的人、因大气污染物质肌肤受到应激的人、因大气污染物质感到肌肤瘙痒的人、因大气污染物质感到肌肤很干的人、因大气污染物质产生肌肤泛红的人、季节交替引起肌肤粗糙的人、生活变化引起皮肤粗糙的人、担心城市的空气(大气)的人、担心因城市的空气(大气)引起瘙痒的人、担心汽车的废气的人、担心PM10、PM2.5的人、担心因PM10、PM2.5引起的瘙痒的人、担心黄沙的人、担心因黄沙引起瘙痒的人、担心花粉的人、担心因花粉引起瘙痒的人、欲进行抗污染的对策的人、担心香烟的烟雾的人、欲屏蔽微粒污染的人、欲保持肌肤清洁的人、欲进行肌肤的抗氧化的人、欲进行肌肤的抗衰老的人、欲冲洗掉大气污染物质的人等。
[制剂形态]
本发明的皮肤障碍改善用组合物可以作为皮肤外用剂,以医药品、准医药品、或化妆品的形态使用。皮肤外用剂中,在不损害本发明的效果的范围内,可以与添加于皮肤外用剂(化妆品、准医药品、医药品)的公知的基剂或载体共同混合而制成组合物。
对于本发明的皮肤障碍改善用组合物而言,作为医药品、准医药品、或化妆品的公知的形态,例如可举出液剂、悬浮剂、乳剂、乳霜剂、软膏剂、凝胶剂、搽剂、乳液剂、气溶胶剂、粉末剂、巴布剂、使无纺布等片材含浸药液的片剂、口红这样的棒剂等。其中,优选为以液剂、悬浮剂、乳剂、霜剂、软膏剂、凝胶剂、乳液剂的形态使用。
特别是作为化妆品组合物时的具体的形态,可举出化妆水、乳液、乳霜、美容液、防晒用化妆品、面膜、护手霜、润肤露、润肤霜这样的基础化妆品;洗面料、卸妆产品、沐浴露、洗发水、冲洗液这样的清洗用化妆品;粉底、化妆基底液、润唇膏、口红、腮红这样的美妆化妆品;沐浴添加剂等。作为这样的化妆品组合物,优选为以大气污染物质所致的影响容易产生的人作为对象,例如更优选为婴儿用、婴幼儿用、儿童用、肌肤脆弱的人用、敏感肌肤用、干燥肌肤用、波动肌肤用、问题肌肤用。
作为基剂或载体,可举出液体石蜡、角鲨烷、凝胶化烃(塑料基质等)、地蜡、α-烯烃低聚物、轻质液体石蜡这样的烃;甲基聚硅氧烷、交联型甲基聚硅氧烷、高度聚合甲基聚硅氧烷、环状有机硅、烷基改性有机硅、交联型烷基改性有机硅、氨基改性有机硅、聚醚改性有机硅、聚甘油改性有机硅、交联型聚醚改性有机硅、交联型烷基聚醚改性有机硅、有机硅·烷基链共改性聚醚改性有机硅、有机硅·烷基链共改性聚甘油改性有机硅、聚醚改性分支有机硅、聚乙烯醇、聚甘油改性分支有机硅、丙烯酸硅、苯基改性有机硅、有机硅树脂这样的有机硅油;乙基纤维素、羟基丙基纤维素、羟基丙基甲基纤维素这样的纤维素衍生物;聚乙烯吡咯烷酮;角叉菜胶;聚乙烯醇缩丁醛;聚乙二醇;二烷;丁二醇己二酸聚酯;肉豆蔻酸异丙酯、肉豆蔻酸辛基十二烷基酯、棕榈酸异丙酯、棕榈酸鲸蜡基酯、异壬酸异壬酯、季戊四醇四2-乙基己酸酯这样的酯类;糊精、麦芽糊精这样的多糖类;乙醇、异丙醇这样的低级醇;乙二醇单甲基醚、乙二醇单乙基醚、乙二醇单丙基醚、二乙二醇单甲基醚、二乙二醇单乙基醚、二乙二醇单丙基醚、二乙二醇单丁基醚、丙二醇单乙基醚、丙二醇单丙基醚、二丙二醇单乙基醚、二丙二醇单丙基醚这样的二元醇醚;聚乙二醇、丙二醇、1,3-丁二醇、甘油、异戊二烯二醇等多元醇;水等水系基剂等。
基剂或载体可以1种单独或组合2种以上使用。
本发明的皮肤障碍改善用组合物在不损害本发明的效果的量和质的范围内,可以根据需要配合在医药品、准医药品或化妆品领域中一般使用的各种成分,例如表面活性剂、保湿剂、稳定化剂、刺激减轻剂、血液循环促进剂、磨砂剂、增粘剂、保存剂、抗氧化剂、着色剂、珠光赋予剂、分散剂、螯合剂、pH调节剂、香料、紫外线吸收成分、紫外线散射成分、清洗成分、抗菌成分、抗炎成分、紧致成分、维生素类、肽或其衍生物、氨基酸或其衍生物、角质柔软成分、细胞活化成分等。应予说明,这些成分可以1种单独或任意组合配合2种以上。并且,这些成分可以与公知的基剂或载体一起混合而配合于皮肤障碍改善用组合物。根据常规方法对这些成分进行处理也能够制造本发明的皮肤障碍改善用组合物。
作为表面活性剂,例如可举出山梨糖醇酐单异硬脂酸酯、山梨糖醇酐单月桂酸酯、山梨糖醇酐单棕榈酸酯、山梨糖醇酐单硬脂酸酯、二甘油山梨糖醇酐五-2-乙基己酸酯、二甘油山梨糖醇酐四-2-乙基己酸酯这样的山梨糖醇酐脂肪酸酯类;单硬脂酸丙二醇酯这样的丙二醇脂肪酸酯类;聚氧乙烯氢化蓖麻油40(HCO-40)、聚氧乙烯氢化蓖麻油50(HCO-50)、聚氧乙烯氢化蓖麻油60(HCO-60)、聚氧乙烯氢化蓖麻油80等氢化蓖麻油衍生物;聚氧乙烯(20)山梨糖醇酐单月桂酸酯(聚山梨酯20)、聚氧乙烯(20)山梨糖醇酐单硬脂酸酯(聚山梨酯60)、聚氧乙烯(20)山梨糖醇酐单油酸酯(聚山梨酯80)、聚氧乙烯(20)山梨糖醇酐异硬脂酸酯这样的聚氧乙烯山梨糖醇酐脂肪酸酯类;聚氧乙烯单椰子油脂肪酸甘油酯;甘油烷基醚;烷基葡糖苷;聚氧乙烯十六烷基醚这样的聚氧化烯烷基醚;硬脂胺、油胺这样的胺类;聚氧乙烯·甲基聚硅氧烷共聚物、月桂基PEG-9聚二甲基甲硅烷氧基乙基二甲硅油、PEG-9聚二甲基甲硅烷氧基乙基二甲硅油这样的有机硅系表面活性剂等。
作为保湿成分,例如可举出甘油、1,3-丁二醇、丙二醇、聚乙二醇、二甘油海藻糖这样的多元醇;肝素类似物、硫酸软骨素钠、胶原蛋白、弹性蛋白、角蛋白、几丁质、壳聚糖这样的高分子化合物;甘氨酸、天冬氨酸、精氨酸这样的氨基酸;乳酸钠、尿素、吡咯烷酮羧酸钠这样的天然保湿因子;神经酰胺、胆固醇、磷脂这样的脂质;洋甘菊提取物、金缕梅提取物、绿茶提取物、紫苏提取物这样的植物提取物等。这些保湿成分中,从提高本发明的效果的观点出发,优选配合神经酰胺,特别是更优选配合神经酰胺2。推测由于神经酰胺(特别是神经酰胺2)具有水分保持功能,因此通过与本发明认为有效果的功能成分并用而使用,来提高表皮细胞、真皮细胞中的水分量,能够提高本发明的效果。另外,如实施例5、6所示,在皮肤屏障功能为正常的状态下,有可能大气污染物质对屏障功能的影响小,其他的影响也小。因此,神经酰胺这样的提高皮肤屏障功能的物质有可能能够减少根据本申请发明得到的大气污染物质对皮肤的负面影响。优选的配合量为0.000001~5重量%。
作为稳定化剂,例如可举出聚丙烯酸钠、二丁基羟基甲苯、丁基羟基茴香醚等。
作为刺激减轻剂,例如可举出阿拉伯胶、聚乙烯吡咯烷酮、甘草提取物、海藻酸钠等。
作为血液循环促进剂,例如可举出乙酰胆碱、衣康醇、咖啡因、辣椒素、斑蝥酊、γ-谷维素、生姜酊、姜油酮、千金藤素、日本獐牙菜提取物、单宁酸、辣椒酊、妥拉唑林、烟酸生育酚、烟酸苄酯等。
作为磨砂剂,例如可举出杏核粉末、扁桃仁壳粉、杏仁核粉末、氯化钠粒、橄榄核粉末、海水干燥物粒、小烛树蜡、胡桃壳粉末、樱桃核粉末、珊瑚粉末、木炭粉末、榛子壳粉末、聚乙烯粉末、无水硅酸等。
作为增粘剂,例如可举出瓜尔胶、刺槐豆胶、角叉菜胶、黄原胶、羧甲基纤维素、羟甲基纤维素、羟基乙基纤维素、羟基丙基纤维素、羟基丙基甲基纤维素、聚乙烯醇、聚乙烯吡咯烷酮、羧乙烯基聚合物、丙烯酸甲基丙烯酸烷基酯共聚物、聚乙二醇、膨润土、(丙烯酸羟基乙酯/丙烯酰基二甲基牛磺酸钠)共聚物、(丙烯酰基二甲基牛磺酸铵/乙烯基吡咯烷酮)共聚物等。
作为保存剂,例如可举出苯甲酸、苯甲酸钠、脱氢乙酸、脱氢乙酸钠、对羟基苯甲酸异丁酯、对羟基苯甲酸异丙酯、对羟基苯甲酸丁酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、对羟基苯甲酸苄酯、对羟基苯甲酸甲酯、苯氧基乙醇等。
作为抗氧化剂,例如可举出二丁基羟基甲苯、丁基羟基茴香醚、山梨酸、亚硫酸钠、抗坏血酸、异抗坏血酸、L-半胱氨酸盐酸盐等。
作为着色剂,可举出无机颜料、天然色素等。
作为珠光赋予剂,例如可举出二硬脂酸乙二醇酯、单硬脂酸乙二醇酯、二硬脂酸三乙二醇酯等。
作为分散剂,例如可举出焦磷酸钠、六偏磷酸钠、聚乙烯醇、聚乙烯吡咯烷酮、甲基乙烯基醚/马来酸酐交联共聚物、有机酸等。
作为螯合剂,例如可举出EDTA二钠盐、EDTA·钙·二钠盐等。
作为pH调节剂,例如可举出无机酸(盐酸、硫酸等)、有机酸(乳酸、乳酸钠、柠檬酸、柠檬酸钠、琥珀酸、琥珀酸钠等)、无机碱(氢氧化钾、氢氧化钠等)、有机碱(三乙醇胺、二异丙醇胺、三异丙醇胺等)等。
作为紫外线吸收成分,可举出辛基三嗪酮、二乙氨基羟苯甲酰基苯甲酸己酯、二甲氧基亚苄基二氧杂咪唑啉丙酸辛酯、对甲氧基肉桂酸2-乙基己酯、叔丁基甲氧基二苯甲酰甲烷、苯基苯并咪唑磺酸、甲氧基肉桂酸辛酯、甲氧基肉桂酸乙基己酯等。
作为紫外线散射成分,可举出含水硅酸、硅酸锌、硅酸铈、硅酸钛、氧化锌、氧化锆、氧化铈、氧化钛、氧化铁、无水硅酸等无机化合物,将这些无机化合物用含水硅酸、氢氧化铝、云母、滑石等无机粉体包覆或与聚酰胺、聚乙烯、聚酯、聚苯乙烯、尼龙等树脂粉体复合化而得的物质,进一步用硅油、脂肪酸铝盐等进行处理而得的物质等。
作为清洗成分,可举出月桂酸钾、肉豆蔻酸钾、棕榈酸钾或单硬脂酸钾等碱金属盐、链烷醇酰胺盐或氨基酸盐等皂类、椰油酰谷氨酸钠、椰油酰甲基牛磺酸钠等氨基酸系表面活性剂、月桂基硫酸钠等醚硫酸酯盐、月桂基醚乙酸钠等醚羧酸盐、烷基磺基琥珀酸酯钠等磺基琥珀酸酯盐、椰子油脂肪酸单乙醇酰胺、椰子油脂肪酸时乙醇酰胺等脂肪酸链烷醇酰胺、月桂基磷酸钠、聚氧乙烯月桂基醚磷酸钠等单烷基磷酸酯盐、椰子油脂肪酸酰胺丙基二甲基氨基乙酸甜菜碱、月桂基二甲基氨基乙酸甜菜碱、2-烷基-N-羧甲基-N-羟基乙基咪唑甜菜碱、月桂基羟基磺基甜菜碱和月桂酰酰胺乙基羟基乙基羧甲基甜菜碱羟基丙基磷酸钠等甜菜碱型两性表面活性剂、月桂基氨基丙酸钠等氨基酸型两性表面活性剂等。
作为抗菌成分,可举出洗必泰、水杨酸、苯扎氯铵、利凡诺、乙醇、苄索氯铵、甲酚、葡萄糖酸及其衍生物、碘化聚乙烯吡咯烷酮、碘化钾、碘、异丙基甲基苯酚、三氯卡班、三氯生、光敏剂101号、光敏剂201号、对羟基苯甲酸酯、苯氧乙醇、1,2-戊二醇、盐酸烷基二氨基甘氨酸、吡啶酮乙醇胺盐、咪康唑等。
作为抗炎剂,可举出薁、氨基己酸和氢化可的松等。
作为紧致成分,可举出氧化锌、硫酸锌、尿囊素羟基铝、氯化铝、酚磺酸锌和单宁酸等。
作为维生素类,可举出dl-α-生育酚、乙酸dl-α-生育酚、琥珀酸dl-α-生育酚、琥珀酸dl-α-生育酚钙等的维生素E类;核黄素、黄素单核苷酸、黄素腺嘌呤二核苷酸、核黄素丁酸酯、核黄素四丁酸酯、核黄素5’-磷酸酯钠、核黄素四烟酸酯等维生素B2类;烟酸dl-α-生育酚、烟酸苄酯、烟酸甲酯、烟酸β-丁氧基乙酯、烟酸1-(4-甲基苯基)乙酯等烟酸类;抗坏血酸-A、抗坏血酸单硬脂酸酯、抗坏血酸棕榈酸酯、L-抗坏血酸二棕榈酸酯等维生素C类;甲基橙皮苷、麦角钙化醇、胆钙化醇等的维生素D类;菲醌、金合欢醌等维生素K类、γ-谷维素、二苯甲酰硫胺素、二苯甲酰硫胺素盐酸盐;硫胺素盐酸盐、硫胺素鲸蜡基盐酸盐、硫胺素硫氰酸盐、硫胺素月桂基盐酸盐、硫胺素硝酸盐、硫胺素单磷酸盐、硫胺素赖氨酸盐、硫胺素三磷酸盐、硫胺素单磷酸酯磷酸盐、硫胺素单磷酸酯、硫胺素二磷酸酯、硫胺素二磷酸酯盐酸盐、硫胺素三磷酸酯、硫胺素三磷酸酯单磷酸盐等维生素B1类;盐酸吡哆醇、乙酸吡哆醇、盐酸吡哆醛、5’-磷酸吡哆醛、盐酸吡哆胺等维生素B6类;氰钴胺素、羟钴胺、脱氧腺苷钴胺素等的维生素B12类;叶酸、蝶酰谷氨酸等叶酸类;烟酸、烟酰胺等的烟酸类;泛酸、泛酸钙、泛醇(panthenol)、D-泛酰巯基乙胺、D-泛硫乙胺、辅酶A、泛醇乙醚等泛酸类;生物素、生物胞素等生物素类;抗坏血酸、抗坏血酸钠、脱氢抗坏血酸、抗坏血酸磷酸酯钠、抗坏血酸磷酸酯镁等的作为抗坏血酸衍生物的维生素C类;肉碱、阿魏酸、α-硫辛酸、乳清酸等维生素样作用因子等。
作为肽或其衍生物,可举出角蛋白分解肽、水解角蛋白、胶原蛋白、来自鱼的胶原蛋白、端胶原、明胶、弹性蛋白、弹性蛋白分解肽、胶原蛋白分解肽、水解胶原蛋白、羟丙基氯化铵水解胶原蛋白、弹性蛋白分解肽、刀豆蛋白分解肽、水解刀豆蛋白、丝蛋白分解肽、水解蚕丝、月桂酰水解蚕丝钠、大豆蛋白分解肽、水解大豆蛋白、小麦蛋白、小麦蛋白分解肽、水解小麦蛋白、酪蛋白分解肽、酰化肽(棕榈酰寡肽、棕榈酰五肽、棕榈酰四肽等)等。
作为氨基酸或其衍生物,可举出甜菜碱(三甲基甘氨酸)、脯氨酸、羟脯氨酸、精氨酸、赖氨酸、丝氨酸、甘氨酸、丙氨酸、苯丙氨酸、β-丙氨酸、苏氨酸、谷氨酸、谷氨酰胺、天冬酰胺、天冬氨酸、半胱氨酸、胱氨酸、蛋氨酸、亮氨酸、异亮氨酸、缬氨酸、组氨酸、牛磺酸、γ-氨基丁酸、γ-氨基-β-羟基丁酸、肉碱、肌肽、肌酸等。
作为角质柔软成分,可举出乳酸、水杨酸、水杨酸乙醇酸、葡萄糖酸、柠檬酸、苹果酸、植酸、尿素、硫等。
作为细胞活化成分,可举出γ-氨基丁酸、ε-氨基己酸等氨基酸类、视黄醇、硫胺素、核黄素、盐酸吡哆醇、泛酸类等维生素类、乙醇酸、乳酸等α-羟基酸类、单宁、类黄酮、皂苷、光敏剂301号等。
[物性]
对于本发明的皮肤障碍改善用组合物的pH,只要是在医药上、药理学或生理学被允许的范围内就没有特别限定,作为一个例子,可举出pH为3.0~9.5,优选为3~8,更优选为3~7,进一步优选为3~6,特别优选为4~6的范围。
本发明的皮肤障碍改善用组合物根据需要可以调节成生物体允许的范围内的渗透压比。适当的渗透压比根据应用部位、剂型等不同,通常可举出为0.5~5.0,更优选为0.6~3.0,进一步优选为0.7~2.0的范围。渗透压的调整可以使用无机盐、多元醇和/或糖等利用该技术领域中已知的方法进行。渗透压比基于第十七次修订日本药典为试样的渗透压相对于286mOsm(0.9w/v%氯化钠水溶液)的渗透压之比,渗透压基于日本药典记载的渗透压测定法(冰点下降法)进行测定。应予说明,渗透压比测定用标准液(0.9w/v%氯化钠水溶液)是将氯化钠(日本药典标准试剂)以500~650℃干燥40~50分钟后,在干燥器(硅胶)中放冷,正确称量其0.900g,溶解于精制水,准确制备成100mL,或使用市售的渗透压比测定用标准液(0.9w/v%氯化钠水溶液)。
本发明的皮肤障碍改善用组合物的粘度只要在医药上、药理学或生理学被允许的范围内,则根据配合成分的种类和含量、制剂形态、使用方法等适当地设定。利用旋转粘度计(RE550型粘度计,东机工业社制,转子;1°34‘×R24)测定的20℃下的粘度优选为1mPa·s以上,更优选为2000mPa·s以上,进一步优选为5000mPa·s以上。
[IL-8表达抑制剂]
其它的实施方式中,本发明也可以提供一种含有选自透明质酸及其盐、透明质酸的衍生物及其盐、朝鲜蓟提取物、氨甲环酸及其盐、维氏熊竹叶提取物、山茶提取物、蔷薇提取物、紫苏提取物、黄芩提取物、甘草提取物、甘茶提取物、芦荟叶提取物、野蔷薇果实提取物、黄连提取物、枇杷叶提取物、樱叶提取物、迷迭香叶提取物、紫草叶提取物、鼠尾草叶提取物、百里香提取物、胡萝卜根提取物、尿囊素、乌芬那酯、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及胆固醇类中的至少1种以上的IL-8表达抑制剂。
上述成分的种类、含量、其它成分、制剂形态、物性等基于上述的[皮肤障碍改善用组合物]的项目。
[IL-33表达抑制剂]
其它的实施方式中,本发明还能够提供一种含有选自尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明及其盐、透明质酸及其盐、透明质酸的衍生物及其盐的、氯化镁、胆固醇类、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及乌芬那酯中的至少1种以上的IL-33表达抑制剂。
上述成分的种类、含量、其它的成分、制剂形态、物性等基于上述的[皮肤障碍改善用组合物]的项目。
[其它实施方式]
上述之外,在其它的实施方式中,本发明还可以提供以下内容:
含有至少1种以上的IL-8表达抑制物的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
含有选自透明质酸及其盐、透明质酸的衍生物及其盐、朝鲜蓟提取物、氨甲环酸及其盐、维氏熊竹叶提取物、山茶提取物、蔷薇提取物、紫苏提取物、黄芩提取物、甘草提取物、甘茶提取物、芦荟叶提取物、野蔷薇果实提取物、黄连提取物、枇杷叶提取物、樱叶提取物、迷迭香叶提取物、紫草叶提取物、鼠尾草叶提取物、百里香提取物、胡萝卜根提取物、尿囊素、乌芬那酯、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及胆固醇类中的1种或2种以上的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
含有至少1种以上的水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
含有选自橘果皮提取物、越橘叶提取物、白柳皮提取物、山金车提取物、明日叶提取物、薏苡提取物、银杏叶提取物、姜黄提取物、野蔷薇提取物(玫瑰果提取物)、黄芩提取物、魁蒿提取物、洋甘菊提取物、紫苏叶提取物、桃子提取物、香蜂花提取物、薰衣草提取物、以及N-月桂酰-L-谷氨酸与L-赖氨酸的缩合物的钠盐中的1种或2种以上的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
含有至少1种以上的氧化应激抑制物的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
含有选自黄芩提取物、越橘提取物、水解蜂王浆、葵花油、苦薄荷、甘油葡糖苷、木天蓼提取物、烟酰胺、糖原、积雪草提取物、锦葵提取物、鱼腥草提取物、印度楝提取物、藻类提取物、黄柏提取物、抗坏血酸、银杏叶提取物、甘茶提取物、绿茶提取物、芦荟叶提取物、芙蓉花提取物、紫苏叶提取物、迷迭香叶提取物、鼠尾草叶提取物、柑橘提取物、洋甘菊提取物、甘草提取物、朝鲜蓟提取物、以及桉树提取物中的1种或2种以上的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
含有至少1种以上的IL-33表达抑制物的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
含有选自尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明及其盐、透明质酸及其盐、透明质酸的衍生物及其盐、氯化镁、胆固醇类、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及乌芬那酯中的1种或2种以上的组合物的、在制造大气污染物质所致的皮肤障碍改善剂中的使用;
包括将含有至少1种以上的IL-8表达抑制物的组合物应用于皮肤的步骤的、大气污染物质所致的皮肤障碍的改善方法;
包括将含有选自透明质酸及其盐、透明质酸的衍生物及其盐的、朝鲜蓟提取物、氨甲环酸及其盐、维氏熊竹叶提取物、山茶提取物、蔷薇提取物、紫苏提取物、黄芩提取物、甘草提取物、甘茶提取物、芦荟叶提取物、野蔷薇果实提取物、黄连提取物、枇杷叶提取物、樱叶提取物、迷迭香叶提取物、紫草叶提取物、鼠尾草叶提取物、百里香提取物、胡萝卜根提取物、尿囊素、乌芬那酯、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及胆固醇类中的1种或2种以上的组合物应用于皮肤的步骤的、大气污染物质所致的皮肤障碍的改善方法;
包括将含有至少1种以上的水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质的组合物应用于皮肤的步骤的、大气污染物质所致的皮肤障碍的改善方法;
包括将含有选自橘果皮提取物、越橘叶提取物、白柳皮提取物、山金车提取物、明日叶提取物、薏苡提取物、银杏叶提取物、姜黄提取物、野蔷薇提取物(玫瑰果提取物)、黄芩提取物、魁蒿提取物、洋甘菊提取物、紫苏叶提取物、桃子提取物、香蜂花提取物、薰衣草提取物、以及N-月桂酰-L-谷氨酸与L-赖氨酸的缩合物的钠盐中的1种或2种以上的组合物应用于皮肤的步骤的、大气污染物质所致的皮肤障碍的改善方法;
包括将含有至少1种以上的氧化应激抑制物的组合物应用于皮肤的步骤的、大气污染物质所致的皮肤障碍的改善方法;
包括将含有选自黄芩提取物、越橘提取物、水解蜂王浆、葵花油、苦薄荷、甘油葡糖苷、木天蓼提取物、烟酰胺、糖原、积雪草提取物、锦葵提取物、鱼腥草提取物、印度楝提取物、藻类提取物、黄柏提取物、抗坏血酸、银杏叶提取物、甘茶提取物、绿茶提取物、芦荟叶提取物、芙蓉花提取物、紫苏叶提取物、迷迭香叶提取物、鼠尾草叶提取物、柑橘提取物、洋甘菊提取物、甘草提取物、朝鲜蓟提取物、以及桉树提取物中的1种或2种以上的组合物应用于皮肤的步骤的、大气污染物质所致的皮肤障碍的改善方法;
包括将含有至少1种以上的IL-33表达抑制物的组合物应用于皮肤的步骤的、大气污染物质所致的皮肤障碍的改善方法;以及,
包括将含有选自尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明及其盐、透明质酸及其盐、透明质酸的衍生物及其盐、氯化镁、胆固醇类、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯、以及乌芬那酯中的1种或2种以上的组合物应用于皮肤的、大气污染物质所致的皮肤障碍的改善方法。
上述成分的种类和含量、其它的成分、制剂形态、物性等基于上述的[皮肤障碍改善用组合物]的项目。
实施例
接下来,通过实施例具体说明本发明,本发明并不限于以下的实施例。另外,实施例中示出的“%”只要没有特别明示,表示干燥固体成分换算或实质成分的质量%。
[试验例1:基于大气污染物质的细胞毒性评价]
在24孔板(Cell Bind,Corning公司),使用正常人表皮角化细胞增殖用培养基(仓敷纺织株式会社(Kurabo公司)),将正常人表皮角化细胞(Kurabo公司,Human EpidermalKeratinocyte:NHEK)以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使4种大气污染物质以各浓度溶解而得的培养基,进一步培养1天。
作为4种大气污染物质,从独立行政法人国立环境研究所购入汽车尾气(VehicleExhaust Particles:VEP,NIES CRM No.8,浓度:10μg/mL,25μg/mL,或者50μg/mL)、城市大气粉尘(Urban Aerosols:UA,NIES CRM No.28,浓度:10μg/mL,25μg/mL,或者50μg/mL)、戈壁黄沙(Gobi Kosa Dust:GKD,NIES CRM No.30,浓度:10μg/mL,25μg/mL,或者50μg/mL)、从关东化学株式会社购入柳杉花粉(Ceder Pollen:CP,产品编号:10901,浓度:250μg/mL,500μg/mL,或者1000μg/mL)来使用。这4种大气污染物质的浓度条件在后述的图1~17中也相同。
培养后,将Hoechst 33342(Molecular Device公司)在培养基中稀释,与孔内培养基进行置换。在室温下染色10分钟后,用ImageXpress(Molecular Device公司)进行图像拍摄(16个视场/孔)。用细胞计数程序进行解析,测定细胞数。根据测定结果,将仅添加培养基(对照)的细胞数设为1,算出还添加了大气污染物质的情况下的相对值(图1A~D)。图1A~D中示出了分别使用VEP、UA、GKD、CP作为大气污染物质的结果。
如图1A~D中记载所示,在任一大气污染物质的各浓度下,均没有看到细胞数的显著的降低。
[试验例2:大气污染物质对皮肤的影响评价(基因表达解析)]
在24孔板(Cell Bind,Corning公司)将NHEK以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使4种大气污染物质以各浓度溶解而得的培养基,进一步培养1天。培养后,用PBS(-)清洗2次,使用RNeasy Mini Kit(Qiagen公司)提取RNA后,使用TOYOBO ReverTra Ace qPCR RT Master Mix with gDNARemover(东洋纺株式会社(TOYOBO公司))而制成cDNA。对制成的cDNA使用Premix Ex Taq(注册商标)并通过qRT-PCR进行解析。根据测定结果,将仅添加培养基的(对照)的各基因表达设为1,算出还添加了大气污染物质的情况下的相对值(图2A~D)。图2A~D表示分别使用VEP、UA、GKD、CP作为大气污染物质的结果。应予说明,Taqman Probe从Applied Biosystem公司购入。各Taqman Probe使用GAPDH:Hs02758991_g1、IL-1β:Hs00174097_m1、IL-6:Hs00985639_m1、IL-8:Hs00174103_m1、IL-33:Hs00369211_m1、MMP1:Hs00899658_m1、Hs00234579_m1、CLDN1:Hs00221623_m1、OCLN:Hs00170162_m1。
如图2A~D中记载所示,由所有大气污染物质诱导炎症的IL-6和IL-8的表达上升。由此与其它文献报告同样地示出大气污染物质诱导皮肤的炎症。另一方面,IL-1β、MMP1、MMP9因VEP和UA而表达上升(图2A、B),IL-33因GKD和CP而表达上升(图2C、D),因此给出了根据大气污染物质的种类不同对皮肤的影响不同的启示。本实验体系中,给出了VEP、UA诱导伴随氧化应激的炎症的启示,给出了参与斑点、痤疮等的发病的启示。另外,VEP、UA所致的MMP的活化引发胶原蛋白等细胞外基质的分解、基底膜的破坏,认为会参与皱纹、松弛的形成。另一方面,虽然已知GKD、CP在免疫细胞等中经由Toll样受体(Toll-like receptor:TLR)而提升IL-33的表达,使Th2型免疫活化,但在皮肤中的影响并不清楚。由该结果给出了GKD、CP在皮肤中也诱导相同的响应,通过促进Th2型免疫而影响肌肤功能,参与过敏、特应性皮炎、敏感肌肤等皮肤疾病的形成的启示。
[试验例3:大气污染物质对皮肤的影响评价(氧化应激)]
在24孔板(Cell Bind,Corning公司)将NHEK以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使4种大气污染物质以各浓度溶解而得的培养基,进一步培养1天。培养后,用PBS(-)清洗2次,将CellROX(注册商标)用于氧化应激检测的绿色试剂(Thermo Fisher Scientific公司)和Hoechst 33342在培养基中稀释,与孔内培养基进行置换。在37℃、5%二氧化碳和95%空气的环境下培养30分钟后,用ImageExpress进行图像拍摄(16个视场/孔)。利用荧光强度测定程序和细胞计数程序进行解析,测定单位细胞数的氧化应激活性。根据测定结果,将仅添加培养基(对照)的单位细胞数的氧化应激活性设为1,算出还添加了大气污染物质的情况下的相对值(图3A~D)。
如图3A~D中记载所示,因VEP和UA,在NHEK中氧化应激上升(图3A、B)。由目前为止的结果可知,给出了VEP和UA在皮肤中诱导伴随氧化应激的炎症的启示。另一方面给出了GKD和CP通过不伴有氧化应激的其它路径对皮肤带来影响的启示(图3C、D)。
[试验例4:基于大气污染物质的IL-8表达量的评价]
在24孔板(Cell Bind,Corning公司),将NHEK以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使4种大气污染物质以各浓度溶解而得的培养基,进一步培养1天。培养后,回收上清液(ELISA用样品),利用HumanIL-8/CXCL8DuoSet ELISA Kit(R&D Systems公司)测定IL-8的表达量。另外,用PBS清洗2次除去了上清液的培养板,将Hoechst 33342在培养基中稀释,与孔内培养基进行置换。在37℃、5%二氧化碳和95%空气的环境下培养10分钟后,用ImageExpress进行图像拍摄(16个视场/孔)。用细胞计数程序进行解析,测定细胞数。根据测定结果,将仅添加培养基的(对照)的细胞数、单位细胞数的IL-8表达量分别设为1,算出添加了大气污染物质的情况下的相对值(图4A~D)。
如图4A~D中记载所示,与基因表达同样地IL-8的蛋白质表达量因所有的大气污染物质而增加。
[试验例5:大气污染物质对屏障功能的影响评价(1)]
在12孔板(12mm Transwell(注册商标)with 0.4μm Pore Polyester MembraneInsert,Sterile,Corning公司)的嵌套式培养板,将NHEK以细胞数96000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养3天后,更换为分化诱导培养基(2mM Ca2+Humedia-KG2),培养4天时间。之后,更换为新的分化诱导培养基(2mM Ca2+Humedia-KG2),培养2天时间后,更换为使4种大气污染物质以各浓度溶解而得的分化诱导培养基(2mM Ca2+Humedia-KG2),培养5天时间。从大气污染物质添加日(培养开始后第9天)起,利用Millicell(注册商标)ERS-2Voltohmmeter(Millipore公司)测定嵌套式培养板的电阻值(图5A~D)。各图中,使用的大气污染物质的浓度为VEP50μg/mL,UA50μg/mL,GKD50μg/mL,CP1000μg/mL。各图中,实线表示添加了各大气污染物质的培养基中的测定结果,虚线表示仅添加培养基(对照)的测定结果。使用的大气污染物质的浓度条件在后述的图6~7中也相同。
如图5A~D记载所示,没有看到大气污染物质所致的TER的变化。根据该结果,给出了在皮肤具有正常的屏障功能的情况下,大气污染物质对皮肤的屏障功能的影响小的启示。
[试验例6:大气污染物质对屏障功能的影响评价(2)]
在12孔板(12mm Transwell(注册商标)with 0.4μm Pore Polyester MembraneInsert,Sterile,Corning公司)的嵌套式培养板,将NHEK以细胞数96000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养3天后,更换为使4种大气污染物质以各浓度溶解而得的分化诱导培养基(2mM Ca2+Humedia-KG2),培养6天时间。这期间,利用Millicell(注册商标)ERS-2Voltohmmeter(Millipore公司)测定嵌套式培养板的电阻值(图6A~D)。各图中,实线表示添加了各大气污染物质的培养基中的测定结果,虚线表示仅添加培养基(对照)的测定结果。
如图6A~D记载所示,TER的上升因VEP和UA受到阻碍(图6A、B)。根据该结果,给出了大气污染物质中VEP和UA使皮肤屏障不成熟的情况、皮肤屏障功能降低的情况下的皮肤屏障衰竭加速的启示。
[试验例7:基于大气污染物质的屏障形成机理降低作用机理的阐述]
在48孔板(Cell Bind,Corning公司),将NHEK以细胞数84000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养3天后,更换为使4种大气污染物质以各浓度溶解而得的分化诱导培养基(2mM Ca2+Humedia-KG2),培养3天时间。培养后,用PBS(-)清洗2次,使用RNeasy Mini Kit(Qiagen公司)而提取RNA后,使用TOYOBO ReverTra Ace qPCR RTMaster Mix with gDNA Remover(TOYOBO公司)而制成cDNA。对制成的cDNA使用Premix ExTaq(注册商标)并通过qRT-PCR进行解析。根据测定结果,将仅添加培养基(对照)的各基因表达设为1,算出还添加了大气污染物质的情况下的相对值(图7A~D)。应予说明,TaqmanProbe从Applied Biosystem公司购入。各Taqman Probe使用CLDN1:Hs00221623_m1,OCLN:Hs00170162_m1。
如图7A~D记载所示,因VEP和UA导致构成紧密连接的基因即CLDN1和OCLN的基因表达量降低(图7A、B)。基于试验例5(图5)的结果认为VEP、UA损伤紧密连接而使皮肤的屏障功能降低。
[试验例8:抑制UA所致的IL-8活化的材料的探索]
在24孔板(Cell Bind,Corning公司),将NHEK以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使候补化合物(甘草酸二钾、氨甲环酸、朝鲜蓟提取物(Ichimaru Falcos公司)、生物透明质酸钠HA12NB(资生堂公司)、Oligo-HA4(SIGMA公司)、刺梨提取物(Ichimaru Falcos公司))、尿囊素、乌芬那酯、甘草次酸、胆固醇以各浓度溶解而得的培养基并进行培养。培养24小时后,更换为使UA和候补化合物以各浓度溶解而得的培养基,进一步培养一天。培养后,回收上清液(ELISA用样品),利用Human IL-8/CXCL8 DuoSet ELISA Kit(R&D Systems公司)测定IL-8的表达量。另外,用PBS清洗2次除去了上清液的培养板,将Hoechst 33342在培养基中稀释,与孔内培养基进行置换。在37℃、5%二氧化碳和95%空气的环境下培养10分钟后,利用ImageExpress进行图像拍摄(16个视场/孔)。利用细胞计数程序进行解析,测定细胞数。根据测定结果,将仅添加培养基(对照)的细胞数、单位细胞数的IL-8表达量分别设为1,算出添加了大气污染物质、候补材料的情况下的各相对值(图8A~J)。
如图8A~J记载所示,甘草酸及其盐、氨甲环酸、HA4、朝鲜蓟提取物、生物透明质酸、刺梨提取物、尿囊素、乌芬那酯、甘草次酸、胆固醇抑制了UA所致的IL-8活化。根据该结果,示出抑制了因包括PM2.5等在内的城市大气粉尘引起的皮肤的炎症。
[试验例9:改善UA所致的屏障功能降低的材料的探索]
在12孔板(12mm Transwell(注册商标)with 0.4μm Pore Polyester MembraneInsert,Sterile,Corning公司)的嵌套式培养板,将NHEK以细胞数96000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养3天后,更换为使UA和候补化合物(柑橘果皮提取物(Ichimaru Falcos株式会社制))以各浓度溶解而得的分化诱导培养基(2mMCa2+Humedia-KG2),培养7天时间。从培养开始第9天和第10天,通过Millicell(注册商标)ERS-2Voltohmmeter(Millipore公司)测定嵌套式培养板的电阻值(图9A~B)。
如图9A~B记载所示,根据柑橘果皮提取物,TER上升。根据该结果,给出了柑橘果皮提取物改善因包括PM2.5等在内的城市大气粉尘引起的屏障功能衰竭的启示。
[试验例10:柑橘果皮提取物的屏障功能改善机理的阐述]
在48孔板(Cell Bind,Corning公司),将NHEK以细胞数84000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养3天后,更换为使UA和候补化合物(柑橘果皮提取物(Ichimaru Falcos公司))以各浓度溶解而得的分化诱导培养基(2mM Ca2+Humedia-KG2),培养5天时间或6天时间。培养后,用PBS(―)清洗2次,使用RNeasy Mini Kit(Qiagen公司)而提取RNA后,使用TOYOBO ReverTra Ace qPCR RT Master Mix with gDNA Remover(东洋纺株式会社(TOYOBO公司))而制成cDNA。对制成的cDNA使用Premix Ex Taq(注册商标)并通过qRT-PCR进行解析。根据测定结果,将仅添加培养基(对照)的各基因表达设为1,算出添加了大气污染物质的情况下的相对值(图10A、B)。应予说明,Taqman Probe从Applied Biosystem公司购入。各Taqman Probe使用GAPDH:Hs02758991_g1,CLDN1:Hs00221623_m1(图10A、B)。
如图10A~B记载所示,示出了柑橘果皮提取物使CLDN1(水闸蛋白1)的表达上升,改善在大气污染物质下的屏障功能。
[试验例11:二维皮肤模型中的大气污染物质介由表皮对真皮的影响评价]
在6孔板(Cell Bind,Corning公司),将NHEK以细胞数400000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使汽车尾气(VEP)或城市大气粉尘(UA)以各浓度溶解而得的培养基,进一步培养1天。培养后,回收上清液,利用0.2μm的过滤器(Corning,431222)除去各大气污染物质。此时,为了校正没有介由表皮的影响,在不对NHEK添加的情况下进行相同的处理,将所得到的上清液作为空白(Blank)。接着,在48孔板(Cell Bind,Corning公司),使用人成纤维芽细胞用培养基(Dulbecco‘s ModifiedEagle Medium(Kurabo公司)、10%胎牛血清(MP Bio公司),1%抗菌-抗真菌剂(Gibco公司)),将正常人皮肤线维芽细胞(Kurabo公司,Human Dermal Fibroblast:NHDF)以细胞数40000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为将人成纤维芽细胞用培养基和过滤器过滤而得的培养上清液以1:1混合而成的培养基,进一步培养4天时间。培养后,回收上清液(ELISA用样品),利用Human MMP1 DuoSet ELISAKit(R&D Systems公司)、Human MMP3 DuoSet ELISA Kit(R&D Systems公司)测定MMP1和MMP3的表达量。另外,用PBS清洗2次除去了上清液的培养板,将Hoechst 33342在培养基中稀释,与孔内培养基进行置换。在37℃、5%二氧化碳和95%空气的环境下培养10分钟后,用ImageExpress进行图像拍摄(16个视场/孔)。利用细胞计数程序进行解析,测定细胞数。根据测定结果,将空白组的仅添加培养基(空白对照)的单位细胞数的MMP1表达量、MMP3表达量分别设为1,算出添加了大气污染物质的情况下的各相对值(图11A~D)。
如图11A~D记载所示,VEP、UA经由表皮细胞,使成纤维芽细胞的MMP1、MMP3活化,参与皱纹形成。
[试验例12:三维皮肤模型中的大气污染物质介由表皮对真皮的影响评价]
对由人正常皮肤角化细胞·纤维芽细胞构成的再构建模型(Kurabo公司,EFT―400)使用EFT―400用培养基(Kurabo公司,EFT-400ASY),在37℃、5%二氧化碳和95%空气的环境下培养24小时。培养后,从表皮上表面添加以各浓度溶解有汽车尾气或城市大气粉尘的PBS,进一步培养3天。培养后,回收培养基(ELISA用样品),利用Human MMP1 DuoSetELISA Kit(R&D Systems公司)、Human MMP3 DuoSet ELISA Kit(R&D Systems公司)测定MMP1和MMP3的表达量。根据测定结果,将仅添加PBS(对照)的每个孔的MMP1表达量、MMP3表达量分别设为1,算出添加了大气污染物质的情况下的各相对值(图12A~D)。
如图12A~D记载所示,三维模型中看到了VEP、UA所致的MMP1的表达上升、UA所致的MMP1的表达上升。以上示出大气污染物质经由表皮而诱导氧化应激,从而使真皮的蛋白质分解体系活化。
[试验例13:大气污染物质对斑点的影响评价]
在24孔板(Cell Bind,Corning公司),将NHEK以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使汽车尾气或城市大气粉尘以各浓度溶解而得的培养基,进一步培养1天。培养后,用PBS(-)清洗2次,使用RNeasyMini Kit(Qiagen公司)而提取RNA后,使用TOYOBO ReverTra Ace qPCR RT Master Mixwith gDNA Remover(东洋纺株式会社(TOYOBO公司))而制成cDNA。对制成的cDNA使用Premix Ex Taq(注册商标)并通过qRT-PCR进行解析。根据测定结果,将仅添加培养基(对照)的各基因表达设为1,算出还添加了大气污染物质的情况下的相对值(图13A、B)。应予说明,Taqman Probe从Applied Biosystem公司购入。各Taqman Probe使用GAPDH:Hs02758991_g1、PTGS2:Hs00153133_m1。
如图13A、B记载所示,由于VEP、UA,从表皮产生而促进黑色素合成的PGE2(前列腺素E2)的基因表达量上升。以上,给出了VEP和UA可能参与斑点形成的启示。
[试验例14:二维皮肤模型中的大气污染物质介由表皮对黑色素细胞的影响评价]
在6孔板(Cell Bind,Corning公司),将NHEK以细胞数400000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使城市大气粉尘以各浓度溶解而得的培养基,进一步培养1天。培养后,回收上清液,利用0.2μm的过滤器(Corning公司,431222)除去大气污染物质。此时,为了校正没有介由表皮的影响,在不对NHEK添加的情况下进行相同的处理,将所得到的上清液作为空白。接着,在48孔板(Cell Bind,Corning公司),使用正常人表皮黑色素细胞专用培养基(Kurabo公司,DermaLife Ma Comp kit),将正常人表皮黑色素细胞(Kurabo公司,Human Epidermal Melanocyte:NHEM)以细胞数40000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为将正常人表皮黑色素细胞专用培养基和过滤器过滤的培养上清液以1:1混合而得的培养基,进一步培养4天时间。培养后,用PBS(-)清洗2次,使用RNeasy Mini Kit(Qiagen公司)而提取RNA后,使用TOYOBO ReverTra Ace qPCR RT Master Mix with gDNA Remover(东洋纺株式会社(TOYOBO公司))而制成cDNA。对制成的cDNA使用Premix Ex Taq(注册商标)并通过qRT-PCR进行解析。根据测定结果,将空白组的仅添加培养基(空白对照)的各基因表达设为1,算出还添加了大气污染物质的情况下的相对值(图14)。应予说明,Taqman Probe从AppliedBiosystem公司购入。各Taqman Probe使用GAPDH:Hs02758991_g1、TYR:Hs00165976_m1。
如图14记载所示,由于UA,看到了黑色素合成相关因子TYR(酪氨酸酶)的表达上升趋势。
[试验例15:三维皮肤模型中的大气污染物质介由表皮对黑色素细胞的影响评价]
对由表皮角化细胞·黑色素细胞构成的皮肤三维模型(Kurabo公司,MEL-300A)使用表皮模型培养用培养基(Kurabo,EPI-100LLMM),在37℃、5%二氧化碳和95%空气的环境下培养24小时。培养后,从表皮上表面添加以各浓度溶解有汽车尾气或城市大气粉尘的PBS,进一步培养1天。培养后,用PBS(―)清洗,回收组织后,用生物捣碎器(Nippi公司)粉碎组织。其后,使用RNeasy Tissue Mini Kit(Qiagen公司)而提取RNA后,使用TOYOBOReverTra Ace qPCR RT Master Mix with gDNA Remover(东洋纺株式会社(TOYOBO公司))而制成cDNA。对制成的cDNA使用Premix Ex Taq(注册商标)并通过qRT-PCR进行解析。根据测定结果,将仅添加PBS(对照)的各基因表达设为1,算出还添加了大气污染物质的情况下的相对值(图15A~C)。应予说明,Taqman Probe从Applied Biosystem公司购入。各TaqmanProbe使用GAPDH:Hs02758991_g1、PTGS2:Hs00153133_m1、TYR:Hs00165976_m1。
如图15A~C记载所示,三维模型中由于UA,也看到了PGE2、TYR等促进黑色素产生的因子的表达上升,是与二维模型相关的数据,示出了UA介由表皮促进黑色素产生,参与斑点形成。另外,对于VEP,看到了PGE2的表达上升,给出了可能参与斑点形成的启示。根据以上,示出了大气污染物质介由表皮促进斑点形成。
[试验例16:抑制大气污染物质所致的氧化应激的材料的探索]
在96孔板(Cell Bind,Corning公司),将NHEK以细胞数15000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使候补化合物(黄芩根提取物(丸善制药社)、越橘叶提取物(Ichimaru Falcos公司)、水解蜂王浆(KatakuraChikkarin公司)、葵花籽油(RAHN公司)、苦薄荷(SEDERMA公司)、甘油葡糖苷、猕猴桃果实提取物(丸善制药公司)、烟酰胺、糖原)以各浓度溶解而得的培养基并进行培养。培养24小时后,更换为使城市大气粉尘和候补化合物以各浓度溶解而得的培养基,进一步培养一天。培养后,用PBS(-)清洗2次,将CellROX(注册商标)用于氧化应激检测的绿色试剂(ThermoFisher Scientific公司)和Hoechst 33342在培养基中稀释,与孔内培养基进行置换。在37℃、5%二氧化碳和95%空气的环境下培养30分钟后,用ImageExpress进行图像拍摄(16个视场/孔)。用荧光强度测定程序和细胞计数程序进行解析,测定单位细胞数的氧化应激活性。根据测定结果,将仅添加培养基(对照)的单位细胞数的氧化应激活性设为1,算出还添加了大气污染物质的情况下的相对值(图16A~I)。
如图16A~I记载所示,给出了黄芩根提取物、越橘叶提取物、水解蜂王浆、葵花籽油、苦薄荷、甘油葡糖苷、猕猴桃果实提取物、烟酰胺、糖原抑制UA所致的氧化应激的活化的启示。
[试验例17:抑制大气污染物质所致的MMP1的材料的探索]
在96孔板(Cell Bind,Corning公司),将NHEK以细胞数15000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使候补化合物(黄芩根提取物(丸善制药)、芦笋叶提取物(拜耳公司)、锦葵花提取物(丸善制药社)、越橘叶提取物(Ichimaru Falcos公司)、鱼腥草提取物(Ichimaru Falcos公司)、印度楝叶提取物(Ichimaru Falcos公司)、藻类提取物(Ichimaru Falcos公司)、苦薄荷(SEDERMA公司))以各浓度溶解而得的培养基并进行培养。培养24小时后,更换为使城市大气粉尘和候补化合物以各浓度溶解而得的培养基,进一步培养一天。培养后,回收上清液(ELISA用样品),利用Human MMP1 DuoSet ELISA Kit(R&D Systems公司)测定MMP1的表达量。另外,用PBS(―)清洗2次除去了上清液的培养板,将Hoechst 33342在培养基中稀释,与孔内培养基进行置换。在37℃、5%二氧化碳和95%空气的环境下培养10分钟后,利用ImageExpress进行图像拍摄(16个视场/孔)。用细胞计数程序进行解析,测定细胞数。根据测定结果,将仅添加培养基(对照)的单位细胞数的MMP1的表达量分别设为1,算出添加了大气污染物质、候补材料的情况下的各相对值(图17A~H)。
如图17A~H记载所示,给出了黄芩根提取物、芦笋叶提取物、锦葵花提取物、越橘叶提取物、鱼腥草提取物、印度楝叶提取物、藻类提取物、苦薄荷抑制UA所致的MMP1的表达上升的启示。
[试验例18:抑制CP所致的IL-33表达增加的材料的探索]
在24孔板(Cell Bind,Corning公司),将NHEK以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使候补化合物(尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明盐酸盐、苯海拉明、透明质酸钠、氯化镁、胆固醇、甘草酸二钾、苯海拉明和胆固醇同时添加、甘草酸二钾和胆固醇的同时添加)和CP以各浓度溶解而得的培养基,进一步培养6小时。培养后,从细胞提取总RNA。通过qRT-PCR测定IL-33的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与对照组的比较,以*P<0.05、**P<0.01、***P<0.001表示。(图18A~L)。
如图18A~L记载所示,给出了尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明盐酸盐、苯海拉明、透明质酸钠、氯化镁、胆固醇、甘草酸二钾、这些多个成分的同时添加抑制CP所致的IL-33表达上升的启示。
[试验例19:抑制GKD所致的IL-33表达增加的材料的探索]
在24孔板(Cell Bind,Corning公司),将NHEK以细胞数80000个细胞/孔进行播种。在37℃、5%二氧化碳和95%空气的环境下培养24小时后,更换为使候补化合物(乌芬那酯、苯海拉明、甘草次酸、胆固醇、利多卡因)和GKD以各浓度溶解而得的培养基,进而培养24小时。培养后,从细胞提取总RNA。通过qRT-PCR测定IL-33的mRNA表达,利用GAPDH表达进行标准化。结果以平均±标准偏差(n=3)表示。P值通过邓奈特检验,利用与对照组的比较,以*P<0.05、**P<0.01、*P<0.001表示。(图19A~E)。
如图19A~E记载所示,给出了乌芬那酯、苯海拉明、甘草次酸、胆固醇、利多卡因抑制GKD所致的IL-33表达上升的启示。
下述示出处方例。处方例中的含量均为质量%。
处方例1化妆水
/>
处方例2乳液
/>
处方例3霜
/>
/>
处方例4O/W防晒凝胶
/>
处方例5W/O防晒乳液
/>
处方例6清洗剂(全身沐浴液)
/>
处方例7霜
处方例8霜
处方例9霜
处方例10霜
处方例11霜
处方例12霜
处方例13霜
处方例14霜
/>
Claims (12)
1.组合物在制造用于抑制大气污染物质所致的皮肤障碍的IL-8表达的IL-8表达抑制物中的应用,
所述组合物含有选自甘草酸及其盐、氨甲环酸、4糖的透明质酸低聚糖、朝鲜蓟提取物、刺梨提取物、尿囊素、乌芬那酯、甘草次酸、以及胆固醇中的1种或2种以上。
2.根据权利要求1所述的应用,其中,所述皮肤障碍为皮肤炎症和/或瘙痒。
3.根据权利要求1或2所述的应用,其中,所述大气污染物质为选自汽车尾气、城市大气粉尘、花粉以及砂尘中的至少1种。
4.组合物在制造用于促进大气污染物质所致的皮肤障碍的水闸蛋白表达和/或闭锁蛋白表达的水闸蛋白表达促进物质和/或闭锁蛋白表达促进物质中的应用,
所述组合物含有选自橘果皮提取物、越橘叶提取物、白柳皮提取物、山金车提取物、明日叶提取物、薏苡提取物、银杏叶提取物、姜黄提取物、野蔷薇提取物(玫瑰果提取物)、黄芩提取物、魁蒿提取物、洋甘菊提取物、紫苏叶提取物、桃子提取物、香蜂花提取物、薰衣草提取物以及N-月桂酰-L-谷氨酸与L-赖氨酸的缩合物的钠盐中的1种或2种以上。
5.根据权利要求4所述的应用,其中,所述皮肤障碍是因皮肤屏障功能的降低和/或不成熟引起的。
6.根据权利要求4或5所述的应用,其中,所述大气污染物质为选自汽车尾气、城市大气粉尘、花粉以及砂尘中的至少1种。
7.组合物在制造用于抑制大气污染物质所致的皮肤障碍的氧化应激的氧化应激抑制物中的应用,
所述组合物含有选自黄芩提取物、越橘提取物、水解蜂王浆、葵花油、苦薄荷、甘油葡糖苷、木天蓼提取物、烟酰胺、糖原、积雪草提取物、锦葵提取物、鱼腥草提取物、印度楝提取物、藻类提取物、黄柏提取物、抗坏血酸、银杏叶提取物、甘茶提取物、绿茶提取物、芦荟叶提取物、芙蓉花提取物、紫苏叶提取物、迷迭香叶提取物、鼠尾草叶提取物、柑橘提取物、洋甘菊提取物、甘草提取物、朝鲜蓟提取物以及桉树提取物中的1种或2种以上。
8.根据权利要求7所述的应用,其中,所述皮肤障碍为选自肌肤的皱纹、斑点、痤疮和松弛中的至少1种。
9.根据权利要求7或8所述的应用,其中,所述大气污染物质为选自汽车尾气、城市大气粉尘、花粉以及砂尘中的至少1种。
10.组合物在制造用于抑制大气污染物质所致的皮肤障碍的IL-33表达的IL-33表达抑制物中的应用,
所述组合物含有选自尿囊素、利多卡因、异丙基甲基苯酚、苯海拉明及其盐、透明质酸及其盐、透明质酸的衍生物及其盐、氯化镁、胆固醇类、甘草酸及其盐、甘草次酸及其盐、甘草次酸十八酯以及乌芬那酯中的1种或2种以上。
11.根据权利要求10所述的应用,其中,所述皮肤障碍为选自瘙痒、湿疹、皮肤炎、皮疹、荨麻疹以及糜烂中的至少1种。
12.根据权利要求10或11所述的应用,其中,所述大气污染物质为选自汽车尾气、城市大气粉尘、花粉以及砂尘中的至少1种。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017203837 | 2017-10-20 | ||
JP2017-203837 | 2017-10-20 | ||
JP2018-147129 | 2018-08-03 | ||
JP2018147129 | 2018-08-03 | ||
CN201880067463.6A CN111246888A (zh) | 2017-10-20 | 2018-10-22 | 皮肤障碍改善用组合物 |
PCT/JP2018/039242 WO2019078370A1 (ja) | 2017-10-20 | 2018-10-22 | 皮膚障害改善用組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880067463.6A Division CN111246888A (zh) | 2017-10-20 | 2018-10-22 | 皮肤障碍改善用组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116870157A true CN116870157A (zh) | 2023-10-13 |
Family
ID=66173971
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880067463.6A Pending CN111246888A (zh) | 2017-10-20 | 2018-10-22 | 皮肤障碍改善用组合物 |
CN202310702778.6A Pending CN116870157A (zh) | 2017-10-20 | 2018-10-22 | 皮肤障碍改善用组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880067463.6A Pending CN111246888A (zh) | 2017-10-20 | 2018-10-22 | 皮肤障碍改善用组合物 |
Country Status (3)
Country | Link |
---|---|
JP (2) | JPWO2019078370A1 (zh) |
CN (2) | CN111246888A (zh) |
WO (1) | WO2019078370A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117442598A (zh) * | 2023-12-25 | 2024-01-26 | 天津嘉氏堂科技有限公司 | 硝酸酯类化合物在制备改善敏感肌表皮屏障产品中的应用 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2020196484A1 (zh) * | 2019-03-28 | 2020-10-01 | ||
JP7421298B2 (ja) * | 2019-10-02 | 2024-01-24 | 花王株式会社 | Brg-1発現促進剤 |
KR102355104B1 (ko) * | 2020-03-06 | 2022-01-26 | 충남대학교산학협력단 | 순무를 포함한 복합추출물을 유효성분으로 하는 호흡기 질환의 예방 및 치료용 약학적 조성물 및 식품 조성물 |
KR102355106B1 (ko) * | 2020-03-08 | 2022-01-26 | 충남대학교산학협력단 | 도라지를 포함한 복합추출물을 유효성분으로 하는 호흡기 질환의 예방 및 치료용 약학적 조성물 및 식품 조성물 |
JP6763497B1 (ja) * | 2020-03-25 | 2020-09-30 | 大正製薬株式会社 | ミネラル代謝異常抑制剤 |
JP2021155355A (ja) * | 2020-03-26 | 2021-10-07 | ピアス株式会社 | 皮膚外用剤 |
CN111557867B (zh) * | 2020-04-21 | 2022-12-06 | 昌正医疗(苏州)有限公司 | 一种婴幼儿舒缓膏及其制备方法 |
JP2021183571A (ja) * | 2020-05-22 | 2021-12-02 | ちふれホールディングス株式会社 | 美容用組成物 |
JPWO2022034833A1 (zh) * | 2020-08-11 | 2022-02-17 | ||
CN112022895B (zh) * | 2020-09-18 | 2022-04-19 | 山东华熙海御生物医药有限公司 | 一种用于皮肤屏障修复的组合物及其制备方法 |
TW202237061A (zh) * | 2020-12-15 | 2022-10-01 | 日商資生堂股份有限公司 | 表皮幹細胞增加促進劑 |
KR102378053B1 (ko) * | 2020-12-24 | 2022-03-25 | 주식회사 조에바이오 | 유해물질 및 광에 대한 피부보호용 조성물 |
KR102335297B1 (ko) * | 2021-04-20 | 2021-12-03 | 주식회사 현대바이오랜드 | 초고압 처리된 아티초크 잎, 동백나무 잎 및 케이퍼 열매 복합 추출물을 함유하는 외부자극에 의한 가려움증 완화 또는 피부진정용 화장료 조성물 |
JP7285504B2 (ja) * | 2021-10-14 | 2023-06-02 | 国立大学法人東海国立大学機構 | 頭皮状態改善剤及びそれを含有する化粧料 |
WO2024096720A1 (ko) * | 2022-11-04 | 2024-05-10 | 주식회사 에버바이오 | 황금 추출물을 유효성분으로 포함하는 피부 보호용 화장료 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06100451A (ja) * | 1992-09-18 | 1994-04-12 | Kowa Co | 皮膚外用剤 |
JPH09291012A (ja) * | 1996-04-25 | 1997-11-11 | Sunstar Inc | 消炎性皮膚化粧料 |
WO2003026606A1 (fr) * | 2001-09-25 | 2003-04-03 | Sekisui Chemical Co., Ltd. | Compositions ameliorant la fonction barriere de la peau |
JP5102506B2 (ja) * | 2006-03-17 | 2012-12-19 | 第一三共ヘルスケア株式会社 | 抗炎症用医薬組成物 |
JP5117110B2 (ja) * | 2007-05-28 | 2013-01-09 | 生化学工業株式会社 | I型アレルギー疾患治療剤 |
JP4754532B2 (ja) * | 2007-07-09 | 2011-08-24 | 生化学工業株式会社 | ヒアルロン酸オリゴ糖を有効成分とする治療剤 |
KR101445100B1 (ko) * | 2012-12-14 | 2014-10-07 | 한국콜마주식회사 | 돌단풍 추출물을 포함하는 항염용 조성물 |
WO2014138897A1 (en) * | 2013-03-14 | 2014-09-18 | Anacoti Ltd. | Hyaluronic acid derivatives |
EP3089729A4 (en) * | 2014-01-03 | 2017-06-14 | Scioderm Inc. | Allantoin compositions for treating inflammatory skin conditions |
JP6589364B2 (ja) * | 2014-05-22 | 2019-10-16 | ライオン株式会社 | 外用剤組成物及び抗炎症作用増強剤 |
JP2016088929A (ja) * | 2014-10-30 | 2016-05-23 | 日光ケミカルズ株式会社 | 汚染防止剤及びこれを含有する汚染防止用化粧料又は汚染防止用皮膚外用剤 |
CN109715250A (zh) * | 2015-10-02 | 2019-05-03 | 科罗拉多州立大学董事会法人团体 | 局部用水飞蓟宾制剂及其用途 |
US10206868B2 (en) * | 2015-12-30 | 2019-02-19 | Mary Kay Inc. | Topical compositions |
JP6718728B2 (ja) * | 2016-04-06 | 2020-07-08 | キユーピー株式会社 | アンチポリューション剤およびアンチポリューション用皮膚外用組成物 |
CN107137342A (zh) * | 2017-07-04 | 2017-09-08 | 广东东阳光药业有限公司 | 一种含有冬虫夏草提取物的舒敏修护喷雾及其制备方法 |
-
2018
- 2018-10-22 CN CN201880067463.6A patent/CN111246888A/zh active Pending
- 2018-10-22 JP JP2019548838A patent/JPWO2019078370A1/ja not_active Withdrawn
- 2018-10-22 WO PCT/JP2018/039242 patent/WO2019078370A1/ja active Application Filing
- 2018-10-22 CN CN202310702778.6A patent/CN116870157A/zh active Pending
-
2023
- 2023-08-04 JP JP2023127707A patent/JP2023133599A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117442598A (zh) * | 2023-12-25 | 2024-01-26 | 天津嘉氏堂科技有限公司 | 硝酸酯类化合物在制备改善敏感肌表皮屏障产品中的应用 |
CN117442598B (zh) * | 2023-12-25 | 2024-03-12 | 天津嘉氏堂科技有限公司 | 硝酸酯类化合物在制备改善敏感肌表皮屏障产品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2023133599A (ja) | 2023-09-22 |
CN111246888A (zh) | 2020-06-05 |
JPWO2019078370A1 (ja) | 2020-11-05 |
WO2019078370A1 (ja) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116870157A (zh) | 皮肤障碍改善用组合物 | |
CN105395458B (zh) | 一种本草组合物及其应用 | |
CN107106480B (zh) | 含有盐单胞菌发酵提取物的化妆品组合物及其用途 | |
JP7325170B2 (ja) | 美容組成物及びミトコンドリアトランスファー促進剤 | |
TW201438757A (zh) | 抗老化用之皮膚外用組成物及其製造方法 | |
KR101096868B1 (ko) | 피부 외용제 | |
JP7461876B2 (ja) | デビルズクロー抽出物、それを含有する各種組成物及びデビルズクロー抽出物の製造方法 | |
JP2023091082A (ja) | アンチポリューション剤及び皮膚外用組成物 | |
CN113262175B (zh) | 皮肤护理组合物及其使用方法 | |
KR101686112B1 (ko) | 락토바실러스 배양용 배지 조성물, 이를 포함하는 인삼 열매 발효 추출물 및 피부상태 개선용 화장료 조성물 | |
KR102029078B1 (ko) | 새로운 올리고당 화합물 및 이의 미용학적 용도 | |
JP6993076B2 (ja) | 皮下組織構造の改善成分のスクリーニング方法 | |
JP2006056902A (ja) | 幹細胞因子の産生・放出の抑制による掻痒、肌荒れ、敏感肌及び美白用薬剤 | |
JP6235855B2 (ja) | ウスベニアオイ又はブクリョウ、及びカフェイン又はカカオ脂を含有する毛髪用組成物。 | |
EP2902022B1 (en) | Vegfc production promoter | |
JP2022136172A (ja) | 皮膚用組成物 | |
JP2019199437A (ja) | 皮膚外用剤 | |
CN117396180A (zh) | 模拟紫河车的化妆料组合物 | |
JP2013166732A (ja) | エンドセリン作用抑制剤の製造方法及びナガサルオガセ抽出物の製造方法 | |
JP2013194001A (ja) | メラノサイト分化誘導促進剤 | |
WO2006070921A1 (ja) | Ⅳ型およびⅶ型コラーゲン産生促進剤 | |
JP2005029494A (ja) | メラノサイト増殖抑制剤およびこれを含む化粧料 | |
JP2008074730A (ja) | 保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤 | |
KR20170039870A (ko) | 서울오갈피 배아 줄기세포 추출물을 유효성분으로 함유하는 화장료 조성물 | |
JP2023056457A (ja) | 美白剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40092366 Country of ref document: HK |